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The blood brain barrier (BBB) is a semi-permeable membrane separating the brain 
from the bloodstream, preventing many drugs that treat neurological diseases, such as 
Alzheimer’s and Parkinson’s, from reaching the brain. Our project aimed to create a 
novel drug delivery system targeting the brain during neural inflammation. We 
developed a cationic solid lipid nanoparticle (CSLN) complex composed of cationic 
nanoparticles, biotin, streptavidin, and anti-vascular cell adhesion molecule-1 (anti-
VCAM-1) antibodies.  The anti-VCAM-1 antibody is used to target VCAM-1, a cell 
adhesion protein found on the BBB endothelium. VCAM-1 expression is elevated in 
the presence of inflammatory molecules, such as tumor necrosis factor-alpha (TNF-
α). Through the use of a simple BBB model, results showed that our novel drug 
delivery system experienced some level of success in targeting the brain 
inflammation due to increasing TNF-α concentrations. This is promising for drug 
delivery research and provides support for VCAM-1 targeting using more robust and 








DRUG DELIVERY THROUGH THE BLOOD-BRAIN BARRIER THROUGH USE 






Team B3: Team Blood Brain Barrier 
 
Sakib Adnan, Regina Borsellino, Alice He, Somdutta Mukherjee, Victor Peng, 
Karthya Potti, Kelly Shih, Janina Vaitkus, Victor Wang, Rani Woo, Robert Zhang 
 
 
Thesis submitted in partial fulfillment of the requirements of the Gemstone Program 











Dr. Jose Helim Aranda-Espinoza 
Dr. Zhihong Nie 
Dr. Avis Cohen 
Dr. Kimberly Stroka 
Dr. Heather Hayenga 




























© Copyright by 
Team B3 
Sakib Adnan, Regina Borsellino, Alice He, Somdutta Mukherjee, Victor Peng, 






























We would like to first thank our mentor, Dr. Helim Aranda-Espinoza for his guidance 
over the past three years along with all the members of his lab. We would also like to 
thank our discussants, Dr. Zhihong Nie, Dr. Avis Cohen, Dr. Kimberly Stroka, Dr. 
Heather Hayenga, and Dr. Daniel Butts for taking the time to review our thesis and 
give us feedback. Our thanks is also extended to the Atlantic Coast Conference Inter-
institutional Academic Collaborative (ACCIAC) and the Howard Hughes Medical 
Institute (HHMI) for their generous grants to support our research. Our gratitude also 
goes out to the Gemstone program that gave us the opportunity and funding to engage 
in this team research. Finally, we would like to thank all of our friends and family for 






















Table of Contents 
1. Introduction…………………………………………………………………….... 1 
      1.1 Research Problem………………………………………………………….. 1 
      1.2 Team Research Focus……………………………………………………… 2 
            1.2.1 Research Question………………………………………………….... 3 
      1.3 Research Hypothesis………………………………………………………. 4 
      1.4 Objectives………………………………………………………………….. 5 
      1.5 Research Significance……………………………………………………… 7 
      1.6 Thesis Organization………………………………………………………... 8 
2. Literature Review……………………………………………………………….. 9 
      2.1 Blood Brain Barrier………………………………………………………… 9 
            2.1.1 Substrates and Types of BBB Models……………………………….. 13 
      2.2 Drug Delivery Mechanisms………………………………………………... 16 
            2.2.1 Viruses……………………………………………………………….. 17 
            2.2.2 T-Cells………………………………………………………………... 18 
            2.2.3 Micelles………………………………………………………………. 19 
            2.2.4 Solid Lipid Nanoparticles……………………………………………. 20 
       2.3 Targeting Molecules………………………………………………………. 24 
3. Blood Brain Barrier……………………………………………………………… 28 
       3.1 BBB Background………………………………………………………….. 28 
            3.1.1 BBB Architecture……………………………………………………. 28 
            3.1.2 BBB Differentiation…………………………………………………. 31 
            3.1.3 BBB Permeability……………………………………………………. 34 
            3.1.4 BBB Pathology………………………………………………………. 36 
            3.1.5 BBB Targeting………………………………………………………. 39 
            3.1.6 Project Aims…………………………………………………………. 40 
      3.2 BBB Methodology…………………………………………………………. 41 
            3.2.1 Human Brain Microvascular Endothelial Cell Culture………………. 41 
            3.2.2 Procedure for Changing Media………………………………………. 43 
            3.2.3 Procedure for Splitting Confluent Cells……………………………… 44 
            3.2.4 Thawing HBMECs…………………………………………………... 45 
            3.2.5 Making the BBB Model: Monolayer of Cells on Glass Coverslips….. 46 
            3.2.6 Adding TNF-α……………………………………………………….. 46 
            3.2.7 Immunofluorescent Staining for VCAM-1………………………...… 47 
            3.2.8 Bead Experiments……………………………………………………. 48 
            3.2.9 Imaging Techniques…………………………………………………. 49 
      3.3 BBB Data and Results……………………………………………………... 51 
            3.3.1 HBMEC VCAM-1 Staining…………………………………………. 50 
            3.3.2 HUVEC VCAM-1 Staining………………………………………….. 60 
            3.3.3 HUVEC Bead Experiments………………………………………….. 67 
      3.4 Blood Brain Barrier Discussion……………………………………………. 72 
            3.4.1 Characterizing VCAM-1 Expression under the Influence of TNF-α... 73 
            3.4.2 Characterizing non-specific Absorption in HUVECS……………….. 73 
            3.4.3 Conclusions…………………………………………………………... 80 
4. Nanoparticle Complex…………………………………………………………... 81 
 vi 
      4.1 Nanoparticle Complex Background………………………………………... 81 
            4.1.1 Cationic Solid Lipid Nanoparticles…………………………………... 81 
            4.1.2 Streptavidin………………………………………………………….. 81 
            4.1.3 Biotin………………………………………………………………… 85 
            4.1.4 Complete Complex…………………………………………………... 87 
            4.1.5 Fluorescent Dye……………………………………………………… 88 
      4.2 Nanoparticle Complex Methodology………………………………………. 89 
            4.2.1 Creating the Nanoparticle……………………………………………. 90 
            4.2.2 Adding Streptavidin………………………………………………….. 91 
            4.2.3 Adding Biotinylated Antibody………………………………………. 91 
            4.2.4 Confirmation of the Nanoparticle Complex…………………………. 92 
      4.3 Nanoparticle Complex Data and Results…………………………………... 92 
            4.3.1 Maximize NP Size Uniformity, Reduce Contamination…………….. 92 
                  4.3.1.1 Unfiltered Nanoparticles……………………………………….. 92 
                  4.3.1.2 Filtered Nanoparticles………………………………………….. 95 
            4.3.2 Test that the Nanoparticle can Attach to Streptavidin……………….. 96 
            4.3.3 Test that Streptavidin can Attach to Biotin…………………………... 99 
            4.3.4 Determining the Concentration of Nanoparticles in Solution………... 102 
      4.4 Nanoparticle Complex Discussion…………………………………………. 106 
             4.4.1 Maximize NP Size Uniformity, Reduce Contamination…………….. 106 
             4.4.2 Test that the Nanoparticle can Attach to Streptavidin………………. 109 
             4.4.3 Test that Streptavidin can Attach to Biotin………………………….. 110 
             4.4.4 Determining the Concentration of Nanoparticles in Solution……….. 111 
5. Nanoparticle Complex with BBB Model……………………………………….. 113 
      5.1 Nanoparticle Complex with BBB Model Methodology…………………… 113 
      5.2 Nanoparticle Complex with BBB Model Data and Results……………….. 114 
             5.2.1 Nanoparticle Control Results………………………………………... 114 
             5.2.2 Nanoparticle Complex Results……………………………………… 119 
      5.3 Nanoparticle Complex with BBB Model Discussion……………………… 124 
             5.3.1 Discussion of Image Trends…………………………………………. 124 
             5.3.2 Ranging Effects of TNF-α on Endothelial Cells…………………….. 125 
             5.3.3 Cell-Adhesion Molecule Targeting Capabilities……………………. 126 
6. Conclusion………………………………………………………………………. 131 
      6.1 Blood Brain Barrier Experiments………………………………………….. 131 
      6.2 Nanoparticle Complex Experiments……………………………………….. 132 
      6.3 Combination Experiment…………………………………………………... 134 
      6.4 Experimental Considerations………………………………………………. 135 
            6.4.1 Creating a More Accurate in vitro BBB Model…………………….... 135 
            6.4.2 Fine-Tuning Nanoparticle Creation………………………………….. 137 
            6.4.3 Nanoparticle Complex Physiological Side Effects…………………... 137 
            6.4.4 Conducting Multiple Trials…………………………………………... 138 
      6.5 Future Directions…………………………………………………………... 138 
            6.5.1 In vivo BBB Model Experiments……………………………………. 139 
            6.5.2 Drugs to Replace Fluorescent Dye…………………………………... 139 
7. Bibliography…………………………………………………………………….. 141 
 
 vii 
List of Figures 
 
Figure 1: BBB Composition………………………………………………..…….... 2 
Figure 2: Presence of TNF-α in the regulation of VCAM-1 expression……...…… 5 
Figure 3: The neurovascular unit…………………………………………...……... 10 
Figure 4: Side view of BBB components and their interactions……………....…… 11 
Figure 5: Breakdown of complex TJ components……………………………...….. 12 
Figure 6: In vitro BBB model with Transwell inserts…………………………..... 16 
Figure 7: The virus is first introduced to its protein cargo……………………….... 17 
Figure 8: The stages of typical T-cell response……………………………………..19 
Figure 9: The cross-section view of a micelle………………………..…….……… 20 
Figure 10: The structure of solid lipid nanoparticles…………………..…….…….. 21 
Figure 11: The structure of co-delivery of paclitaxel and siRNA……….……..….. 23 
Figure 12: Cell surface adhesion molecules………………………………..…….... 25 
Figure 13: ICAM-1………………………………………………………….……... 26 
Figure 14: VCAM-1 on the BBB surface…………………………………….……. 27 
Figure 15: Architecture of the BBB……………………………………………..…. 28 
Figure 16: In vivo imaging of a neurovascular unit (NVU)……………………..…. 31 
Figure 17: Composition of the differentiated BBB on a cellular level…………...... 32 
Figure 18: Various cytokines associated with pathological conditions……………. 37 
Figure 19: Composite image of VCAM-1 stained HBMECs with no TNF-α………51 
Figure 20: Composite image of VCAM-1 stained HBMECs with 2 µg/mL TNF-α. 52 
Figure 21: Composite image of VCAM-1 stained HBMECs with 20 µg/mL of  
 TNF-α…………………………………………………………………...53 
Figure 22: Histograms representing the pixel intensity distributions………..…….. 55 
Figure 23: Histograms representing the pixel intensity distributions………..…….. 57 
Figure 24: Trends of VCAM-1 expression in HBMECs in relation to TNF-α……. 59 
Figure 25: VCAM-1 stained HUVECs incubated without TNF-α…………….…... 60 
Figure 26: VCAM-1 stained HUVECs incubated with 2 µg/mL of TNF-α……...... 61 
Figure 27: VCAM-1 stained HUVECs incubated with 20 µg/mL of TNF-α..…….. 62 
Figure 28: Histograms representing the pixel intensity distributions………..….…. 64 
Figure 29: VCAM-1 Expression of HUVECs………………………………………66 
Figure 30: Composite images and histograms depicting bead absorption……..…...67 
Figure 31: Composite images and histograms depicting bead absorption……..…...68 
Figure 32: Composite images and histograms depicting bead absorption……..…...69 
Figure 33: Bead absorption in HUVECs……………………………………………71 
Figure 34: Composition of LDL………………………………………………….... 82 
Figure 35: Schematic diagram of the assembly of CSLN………………….……….83 
Figure 36: Attaching streptavidin to nanoparticles…………………………..…….. 84 
Figure 37: Streptavidin’s four biotin-binding sites……………………………..….. 86 
Figure 38: Completed drug delivery complex…………………………………..…. 88 
Figure 39: Emission spectrum of BODIPY TMR……………………………….. 89 
Figure 40: Typical phospholipid bilayer membrane with transmembrane proteins.. 91 
Figure 41: Three separate photos of the nanoparticles before filtering……….…….93 
Figure 42: Three separate photos of the nanoparticles after filtering…..…………...94 
Figure 43: Shows the size distribution of nanoparticles…………..……………….. 96 
 viii 
Figure 44: NP on biotin-coated slide……………………………….………………  98 
Figure 45: NP on normal slide………………………………………..…………….  98 
Figure 46: NP-strep on biotin-coated slide……………………………..…………..  98 
Figure 47: NP-strep on normal slide…………………………………….…………  98 
Figure 48: S distribution of the nanoparticles before and after filtering….……….. 108 
Figure 49: Composite images of nanoparticle absorption by HUVECS…….…….. 114 
Figure 50: Composite images of nanoparticle absorption by HUVECS……….….. 115 
Figure 51: Composite images of nanoparticle absorption by HUVECS ………...... 116 
Figure 52: Bare nanoparticle absorption in relation to TNF-α……….…...………..118 
Figure 53: Composite images of nanoparticle complex absorption by HUVECS..... 119 
Figure 54: Composite images of nanoparticle absorption by HUVECS…………... 120 
Figure 55: Composite images of nanoparticle absorption by HUVECS…………... 121 



































List of Tables 
 
Table 1: Recipe for HBMEC Media……………………………………………..… 42 
Table 2: Recipe for HUVEC Media……………………………………………..…. 43 
Table 3: Confluency Table……………………………………………………..…... 45 
Table 4: Counting Nanoparticles…………………………………………….…….. 97 
Table 5: Counting Fluorescent Nanoparticles……………………………..……….. 98 
Table 6: Fluorescent Particles in Each Image……………………………..……….. 105 




List of Abbreviations 
 
ACBRI 376 – Applied Cell Biology Research Institute 
ALCAM – Activated Leukocyte Cell Adhesion Molecule 
ALS – Amyotrophic Lateral Sclerosis 
ANG-1 – Angiopoietin-1  
BBB – Blood Brain Barrier 
CBSA – Cationic Bovine Serum Albumin 
CMC – Critical Micelle Concentration 
CNS – Central Nervous System 
CSF – Cerbrospinal Fluid 
CSLN – Cationic Solid Lipid Nanoparticle 
EC – Endothelial Cells 
ECGS – Endothelial Cell Growth Supplement 
FBS – Fetal Bovine Serum 
FGF – Fibroblast Growth Factor 
FITC – Fluorescein Isothiocyanate 
Gb3 – Globotriaosylceramide 
GDNF – Glial-Derived Neurotrophic Factor 
GSL – Glycosphingolipid 
HBMEC – Human Brain Microvascular Endothelial Cell 
HUVEC – Human Umbilical Vein Endothelial Cell 
IDE – Idebenone 
ICAM-1 – Intercellular Adhesion Molecule 1 
ICAM-2 – Intercellular Adhesion Molecule 2 
ISF – Interstitial Fluid 
JAM – Junction Adhesion Molecule 
LDL – Low Density Lipoprotein 
MFI – Mean Fluorescence Intensity 
MPC – Mean Fluorescence Intensity per Cell 
NIH – National Institute of Health 
NP – Nanoparticle 
NVU – Neurovascular Unit 
RPMI – Roswell Park Memorial Institute 
SLC – Solute Carrier Transporter 
SLN – Solid Lipid Nanoparticle 
TEER – Transendothelial Electrical Resistance 
TGF-β – Transforming Growth Factor 
TJ – Tight Junction 
TNF-α – Tumor Necrosis Factor Alpha 
VCAM-1 – Vascular Cell Adhesion Molecule-1 
VLP – Virus-Like Particle
 1 
1. Introduction 
1.1 Research Problem 
Millions of people struggle emotionally and physically with terminal neurological 
pathologies, many of which are rooted in the brain. The blood brain barrier (BBB) is the 
brain’s defense mechanism against outside compounds. The BBB is a highly selective, 
semipermeable membrane that regulates passage of molecules from the circulatory 
system into the central nervous system (CNS). Although the BBB is beneficial in 
protecting the brain from harmful molecules in the bloodstream, it also prevents life-
saving drugs from reaching the CNS. Technology today has advanced to the point where 
pharmaceuticals have the potential to treat and cure specific neurological maladies, yet 
these potentially life-saving medicines are hindered simply by the membrane that filters 
access to the brain. If drug treatments were able to bypass the BBB and gain access to the 
brain, the medical community would be a significant step closer to curing many 
neurological maladies. Diseases such as Alzheimer’s, multiple sclerosis, or meningitis 
would potentially be less harmful and possibly curable. 
The selective permeability of the BBB only allows certain substances directly 
related to maintenance of brain homeostasis and function to diffuse. Certain hydrophobic 
molecules can permeate, whereas hydrophilic molecules such as proteins and peptides are 
prevented from crossing the BBB.1 The complexity of the BBB composition and certain 
pathways for transversal are shown in Figure 1. This constraint severely limits the 
research and development into drugs to treat neurological diseases because of the BBB 
obstacle. Currently, there are a number of ways that researchers have begun to try and 
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permeate the BBB, mostly through transport mechanisms that target certain adhesion 
molecules on the BBB structure to facilitate diffusion. Among those transport 
mechanisms are using T-cells, viruses, micelles, and nanoparticles. However, there is yet 
to be a proven method stable enough to stimulate significant development of additional 
neurological drugs. Thus, this project seeks to find a novel and effective delivery system 
that can cross the BBB so that in the future, researchers may be able to adapt this method 
and carry it further by targeting specific sites beyond the BBB.   
         
Figure 1. Varying methods and pathways of molecular transmigration across the BBB.  
Nature, http://www.nature.com/nrn/journal/v7/n1/fig_tab/nrn1824_F3.html 
 
1.2 Team Research Focus  
This project focuses on finding a novel drug delivery method to permeate the 
BBB. We chose to focus our project on the use of a nanoparticle-antibody complex as a 
transportation method to ferry drugs into the brain and treat neurological diseases. It is 
known that antibody targeting can be used to transport material into individual cells. In 
addition, drugs can be encapsulated through the use of nanoparticles. The focus of this 
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research project is twofold: to create a working in vitro BBB model that simulates the 
complex interactions that a real BBB would have, and to create a nanoparticle-antibody 
complex that will permeate the BBB model. Our targeting method of choice is through 
vascular cell adhesion molecule-1 (VCAM-1), a molecule present on the surface of the 
BBB endothelium. The logic behind our decision is that inflammation in the brain, often 
instigated by disease, results in the presence of a cytokine, tumor necrosis factor alpha 
(TNF-α) which, in turn, up-regulates the presence of VCAM-1. Therefore, neurologically 
diseased brains have increased amounts of VCAM-1. Thus, we decided to use a VCAM-1 
targeting antibody in our nanoparticle-antibody complex to facilitate permeation through 
our in vitro BBB model.  
 
1.2.1 Research Question 
 Specifically, the questions that will be assessed are (1) will an increase in TNF-α 
up-regulate the presence of VCAM-1 on an in vitro BBB model, (2) is it possible to 
construct a cationic solid lipid nanoparticle (CSLN)-antibody complex that targets 
VCAM-1, (3) will the streptavidin-biotin interaction be strong enough to stabilize the 
CSLN-antibody complex, and (4) will targeting VCAM-1 on endothelial cells (EC) be a 
viable way to get drugs encapsulated by a CSLN-antibody complex through the in vitro 
BBB model? Streptavidin and biotin are receptors that we will use to join together the 
nanoparticles and VCAM-1 targeting antibodies. We will use a fluorescent dye 
encapsulated in the nanoparticles to simulate potential drugs. 
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1.3 Research Hypothesis 
The main approach taken was to construct a stable CSLN-antibody complex that 
would permeate the BBB model by targeting VCAM-1. The nanoparticle will serve as a 
vessel for our drug substitute. The biotinylated anti-VCAM-1 antibody is to ensure that 
our vessel is successful in both traversing the BBB and targeting VCAM-1. The stability 
of our drug delivery method is heavily dependent on the streptavidin-biotin complex, 
which is one of the strongest non-cationic bonds formed in nature. 
For the first component of our experiment in creating an in vitro BBB model, we 
expect to be able to successfully create an in vitro BBB model at varying levels of 
inflammation with the use of TNF-α. We used TNF-α because past studies have found 
that the increased presence of TNF-α also up-regulates the expression of VCAM-1 on the 
BBB (see Figure 2).2  
In the second component of our experiment of creating a transport method, we 
expect to create a CSLN-antibody complex using the streptavidin-biotin interaction to 
stabilize the connection between the dye-infused CSLN and VCAM-1 targeting antibody. 
Finally, when combining the CSLN-antibody complex with our in vitro BBB 
model, we expect that the CSLN-antibody complex will permeate the barrier at higher 
levels than the simple nanoparticle control. We also hypothesize that we will see a 
gradual uptrend in uptake of the CSLN-antibody complex by the in vitro BBB model 
with increasing levels of TNF-α.  
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Figure 2. Presence of TNF-α in the regulation of VCAM-1 expression. TNF-α binding to 
cell surface receptors triggers intracellular signaling cascade activation, which results in 
the transcription of VCAM-1.  




Ultimately, the goal of our research was to devise a novel method of drug delivery 
that can be expanded on in the future. We hoped to conclude that targeting VCAM-1 on 
brain ECs would increase the uptake of a modified nanoparticle drug delivery system 
through the BBB.  
Our project focused on three distinct phases: creating an in vitro BBB model that 
mimics the properties of the real barrier, assembling an antibody-nanoparticle complex, 
and combining the two elements to test the complex’s ability to transverse the BBB 
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model. Thus, our BBB sub-team and nanoparticle sub-team worked simultaneously until 
the in vitro BBB model was created and the antibody-nanoparticle complex was 
constructed. The two teams proceeded to work together in testing the CSLN-antibody 
complex’s ability to transverse the BBB model. 
In the first phase in which the in vitro BBB model was created, the first objective 
was to create a dependable, consistent monolayer of Human Brain Microvascular 
Endothelial Cells (HBMECs) and Human Umbilical Vein Endothelial Cells (HUVECs) 
on which to test our experiments. The HBMECs represent the layer of cells on the surface 
of the BBB whereas the HUVECs are a similar type of EC. The next objective in the first 
phase was to add various levels of TNF-α to the monolayer of HUVECs and observe 
immunofluorescent staining of VCAM-1. The third objective was to utilize fluorescent 
microspheres to determine whether the BBB model functions properly in taking up 
molecules.  
Simultaneously occurring was the second phase during which the antibody-
nanoparticle complex was assembled. The first objective was to create the nanoparticle. 
The next objective was to add streptavidin to the nanoparticle so that it would attach to 
the biotinylated anti-VCAM-1. Following the addition of streptavidin to the nanoparticle, 
the next objective was to ensure that the streptavidin-nanoparticle complex would attach 
to biotin by using biotin-coated plates. The final objective was to create the final complex 
and attach biotinylated antibodies to the streptavidin-nanoparticle complex. 
In the final phase where the BBB model and nanoparticle complex were 
combined, the sole objective was to observe whether the CSLN-antibody complex 
crosses the BBB model. Our experiment sought to find correlation between how damaged 
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the BBB was, and how much penetration and attachment our drug delivery method could 
achieve.  
 
1.5 Research Significance 
The conclusion of our research shows that there is another viable method of drug 
delivery through the BBB. Our CSLN-antibody complex encapsulates a drug-simulating 
dye and delivers it across the BBB to targeted cells. The benefits of our research could 
potentially progress the field of drug delivery through the BBB. If our drug delivery 
vehicle were compatible with drugs capable of delaying or curing neurological diseases, 
then this would spur more research and development into creating such drugs. Patients 
afflicted with neurological diseases like Alzheimer’s, multiple sclerosis, or meningitis 
would have more potential for treatment. Also, if treated early enough, it is possible that 
victims would experience just a fraction of the symptoms that they would normally 
experience because of lessened neurological damage. 
These findings can potentially be used to aid other research groups’ methods. 
Given that the CSLN-antibody complex is able to permeate the BBB successfully, other 
researchers can then investigate methods of inserting other drugs into our CSLN, or a 
more efficient means of building the complex for specific diseases. There are also many 
possibilities of improvement to our drug delivery vessel. Modifications to the complex 
could be made, whether to improve binding, add additional binding sites, or add 
additional space for drugs. Similarly, researchers could use our method of forming a 
vessel-binding complex to form other vehicles that carry different drugs to different sites. 
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We hope that our research can be used as a stepping-stone for other researchers to find 
more effective ways of permeating the BBB.  
Not only will this research contribute to the possibility of successfully 
transporting a drug to cure diseases, but it will further general knowledge in the 
neurological and pharmaceutical research field. The molecules could be manipulated so 
that they may possibly serve purposes other than simple drug delivery. 
 
1.6 Thesis Organization 
      This thesis is organized by the order of our experimental process. A literature review 
is presented in Chapter 2 to give additional context to the current stage of BBB 
understanding and drug delivery mechanisms available. Chapters 3 and 4 focus on the in 
vitro BBB model and nanoparticle complex, respectively. Both chapters include a more 
comprehensive background, methodologies for these preliminary experiments, data and 
results, as well as discussion of these preliminary results. Chapter 5 describes the 
combination of the two parts: using our CSLN-antibody complex to test permeability of 
the in vitro BBB model by targeting VCAM-1. This chapter includes a methodology, data 
and results, and a discussion of this main objective. Finally, Chapter 6 provides a 
conclusion that summarizes our objectives and results as well as describes limitations of 
our experiment and possible future directions.  
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2. Literature Review 
2.1 Blood Brain Barrier 
The BBB is the membranous, physical separation of the circulatory system from 
the CNS in an organism. Its presence was discovered in the late 19th century by German 
studies observing that dyes injected into the bloodstream would stain all other organs 
with the exception of the brain and spinal cord.1 It was also found that acids injected 
directly into the brain produced seizures while those injected through other capillaries did 
not.3 Researchers determined from these experiments the presence of a barrier between 
the fluid in the brain and the bloodstream—the BBB. 
The BBB’s main functions are to maintain homeostasis in the CNS, regulate the 
supply and passage of essential nutrients in the brain, protect the brain from extracellular 
objects, and induce inflammation in response to exogenous changes in the 
environment.1,4 To accomplish these tasks, the BBB is composed of a unique 
physiological structure that functions as a selective gateway to the brain. 
Most simply, the BBB is understood as a membrane surrounding capillaries 
running through the brain, separating these capillaries from the fluids of the brain.3 While 
the blood portion of the BBB consists of the thin capillaries surrounding the CNS, the 
barrier portion consists of a monolayer of ECs that surround these capillaries. Individual 
cells of the CNS and circulatory system are in close contact to one another. Most CNS 
cells are no more than 40 µm apart from a capillary.5  
The cellular building blocks of the BBB are brain microvascular ECs, pericytes, 
and astrocytes.6 The ECs are held together by tight junctions (TJs) that control 
permeability through the BBB. The ECs are surrounded by an extracellular matrix called 
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the basement membrane that physically holds the EC layer in place.7 Together these 
components are known as the neurovascular unit (NVU).  
 
Figure 3. The neurovascular unit (NVU) with all of its components. The interactions 
between brain endothelial cells, astrocytes, pericytes, the basal lamina, and microglia 
create the neurovascular units 
Brain Research Reviews, 
http://www.sciencedirect.com/science/article/pii/S0165017310000676. 
 
It is in the basement membrane that pericytes serve their function of providing 
physical support and regulating the ECs.8 Astrocytes surround the basement membrane, 
attached by thin endfeet, and regulate interaction between neurons in the CNS, 
endothelium, and basement membrane of the BBB.9 The direct association between 
astorcytes and ECs of the brain allow astrocytes to secrete substances into the BBB that 
contribute to its differentiation and impermeability. Pericytes are wrapped around the 
ECs to both provide structural support and regulate permeability. Both pericytes and 
astrocytes are essential to the differentiation of the BBB.  
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Figure 4. Side view of BBB components and their interactions. The interactions between 
brain endothelial cells, astrocytes, pericytes, the basal lamina, and microglia create the 
neurovascular units 
Brain Research Reviews, 
http://www.sciencedirect.com/science/article/pii/S0165017310000676. 
 
The EC layer serves as the core of the BBB membrane. The brain is one of the 
most sensitive organs in the body, and thus functions only in certain physiological 
conditions. In order to maintain this strict range of conditions, the ECs serve as a 
selectively permeable membrane that highly regulates the paracellular and transcellular 
diffusion of molecules. Paracellular diffusion is the transport of molecules between 
individual cells, while transcellular diffusion is the transport of molecules through 
individual cells. The ECs allow the passage of small hydrophobic molecules, but retard 
the movement of most hydrophilic molecules through the BBB.10 Only compounds that 
serve to uphold neurological function, such as glucose and amino acids, are able to 
permeate the barrier through the EC’s expression of transport proteins.4 The ECs of the 
brain are highly differentiated from other ECs in the body because of this capacity to 
control molecule passage through unique receptors and transporters.11 
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TJs are another essential component of BBB function and the main structure that 
creates the selectively permeable barrier properties.1 TJs are formed by several proteins 
anchored between ECs, which fuse these cells together to prevent seepage of substances 
between cells.12 These proteins include claudins, occludins, and junction adhesion 
molecules (JAMs). Claudins and occludins work together to form intramembranous 
strands that dictate selective diffusion of hydrophilic molecules.6 Over forty proteins are 
associated with the TJ, making it the most complex element of the body’s vasculature.1 
 
Figure 5. Breakdown of complex TJ components. 




TJ functionality is associated with high transendothelial electrical resistance 
(TEER) values. High TEER values have been associated with the increased selectivity of 
the BBB, as shown by experimental observations tracking membrane electrical resistance 
in developing rat pups.13 With increased electrical resistance, electron microscopy 
showed less atomic diffusion and increased TJ functionality.  
 
2.1.1 Substrates and Types of BBB Models 
The in vivo BBB consists of a single layer of ECs located in the brain capillaries 
that separate the bloodstream from the CNS. In vivo BBB models offer pinpoint 
representativeness of BBB biophysiology, but they are significantly more expensive, 
difficult to use, and limited in producing high throughput experiments when compared to 
in vitro BBB models.14 In vitro BBB models still offer notable representativeness since 
they are commonly composed of a monolayer of brain ECs. At the very least, in vitro 
BBB models will be formed using ECs with similar protein expression found in cortical 
cells. Typically, an EC monolayer is attached upon glass or plastic with another layer of 
material called a substrate. Ideally, the EC monolayer will have similar biological 
properties as HBMECs, which comprise the in vivo BBB. However, porcine and murine 
ECs are usually used for in vitro studies since they are economic and easily obtainable.15 
However, for our purposes, we used HUVECs to form the monolayer as they have been 
shown to mimic many of the same biological functions of HBMECs in the in vitro BBB 
model.16 
            Several components of an in vitro BBB model contribute to the models overall 
ability to biologically represent the true BBB. For example, astrocytes play a crucial role 
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in the in vitro BBB model construct. Co-culture of astrocytes and ECs promotes TJ 
formation between ECs. The use of actual astrocytes in this co-culture, as opposed to 
conditioned media from astrocytes, is important to this model to simulate the cross-talk 
that occurs between astrocytes and ECs. It is expected that a larger astrocyte:EC ratio 
would produce a less permeable, stiffer BBB model, while a smaller ratio would produce 
a more permeable membrane.10 Thus, variations in the astrocyte:EC ratio would mimic 
different BBB pathophysiological states, where a lower astrocyte:EC ratio would 
represent a more compromised BBB. However, astrocyte and EC interactions are not the 
only components that alter BBB permeability and integrity.  More biorepresentatitive 
models of the BBB have used a substrate of appropriate stiffness to represent the natural 
permeability BBB. 
            The Matrigel substrate, which involves a co-culture of HUVECs and mesangial 
cells, has displayed significant biorepresentativeness. Mesangial cells, smooth muscle 
cells that surround blood vessels in the kindeys to regulate blood flow, are sandwiched 
between the HUVECs and the Matrigel substrate to eliminate contact between HUVECs 
and the Matrigel substrate. Interestingly, HUVECs grown directly on Matrigel substrate 
displays limited proliferation and monolayer or network formation. Thus, the Matrigel 
substrate displays acceptable network formation only when the HUVECs are co-cultured 
with mesangial cells.17 Matrigel is a commonly used and commercially available 
basement membrane for growing several cell lines used for in vitro modeling. The 
Matrigel substrate is composed mainly of collagen, laminin, and entactin. Moreover, 
unlike many other commercially available substrates, Matrigel naturally contains several 
growth factors and small amounts of other proteins in unspecified concentrations. 
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Therefore, the Matrigel substrate would not be ideal for our intentions. Since in vitro 
BBB modeling requires precise knowledge of protein concentration, distribution, and 
expression, the Matrigel model includes variability that would interfere with our end 
goals.18 
            Other substrates have been shown to provide appropriate permeability properties 
of the BBB when coated with ECs. Mainly, gelatin-coated and hydroxyapatite-coated 
substrates provide an appropriate environment for EC attachment and proliferation. 
However, gelatin has been shown to dissolve overtime, which ultimately leads to cell 
detachment from the substrate. To bypass this limitation of the gelatin substrate, 
supplemental protein binding methods must be implemented. Hydroxyapatite-coated 
substrates also supports cell attachment, proliferation, and differentiation, but at a greater 
degree than gelatin substrates. Still, hydroxyapatite substrates dissolve overtime as well, 
which mandates supplementary methods to limit cell detachment.19 
A collagen substrate is also suitable for composing in vitro BBB models, and is 
one of the more common substrates currently used. Typically, ECs are co-cultured with 
astrocytes. The ECs and astrocytes are then isolated and transferred onto the collagen 
substrate, ultimately forming a monolayer.20 Collagen has been shown to limit BBB 
permeability, which ultimately augments the barrier’s overall integrity. Commonly, the 
ECs and collagen substrate are inserted into a semi-permeable membrane, typically a 




Figure 6. In vitro BBB model with Transwell inserts. 
European Journal of Pharmaceutics and Biopharmaceutics, 
http://www.sciencedirect.com/science/article/pii/S0939641110003656 
 
Transwell inserts are also used for in vitro BBB modeling. Transwell inserts 
contain a semi-permeable filter coated with a monolayer of ECs, which is submerged in 
media appropriate for the type of ECs. Fibronectin is added to promote adherence of the 
ECs to the filter.20  
Previously, researchers have also used fibronectin-covered polyacrylamide gels, 
coated with HUVEC monolayers to mimic the BBB. Interestingly, this model of the BBB 
involved glass coverslip as the surface for the HUVEC monolayer in place of the 
Transwell insert. This in vitro model of the BBB was also sufficient to promote 
transmigration of neutrophils, as would occur in the in vivo BBB. Moreover, this model 
could be exposed to TNF-α to represent various degrees of BBB pathophysiologies.21 
 
2.2 Drug Delivery Mechanisms 
The treatment of brain diseases requires the infiltration of the BBB.22 We sought 
to develop a novel carrier and method in which to transfer drugs across the BBB. We 
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considered four main possibilities of drug delivery: viruses, T-cells, micelles, and solid 
lipid nanoparticles (SLNs). Although all methods were considered equally possible when 
we began our experiments, we gradually narrowed our choices down based on structure, 
feasibility, and results from prior experiments.  
 
2.2.1 Viruses 
The first option we chose to explore was the use of a virus as a method of drug 
delivery. Human immunodeficiency virus, also known as HIV, enters cells by binding to 
the surface of the body’s cells.  A protein called gp120, which is located on the surface of 
the virus, binds to the CD4 receptor on the surface of a healthy cell. Once bound, the cell 
membranes of the virus and the healthy cell fuse together.23 This is the first step of the 
viral replication cycle, and there is evidence to suggest that this method of entry could 
serve as a drug delivery method, as shown in Figure 7 below. Although HIV was used in 
this example, many particles are able to gain entry into cells. In general, we will refer to 
these as virus-like particles (VLP).  
 
Figure 7. The virus is first introduced to its protein cargo. After full assembly, targeting 
ligands attach themselves to the outer shell of the virus. 




            There are several qualities of the VLP that make them an attractive vehicle for 
drugs. Their ability to hold nucleic acids and small molecules means that there is a way 
for the drug to accompany the VLP through the cell. VLPs usually store their genetic 
materials within the viral capsids.24 There are generally two methods of inserting cargo 
into the VLP. First, an “osmotic shock” of intact VLPs causes the spaces in between the 
viruses to increase. This gives enough room for nucleic acids to slip through.  The second 
method is an in vitro assembly of the subunits of the VLPs with the presence of the 
nucleic acids.25 There are several different viruses that have been explored thus far as 
drug carrying vehicles. They are: cowpea chlorotic mottle virus, the brome mosaic virus, 
the Simian virus, the red clover necrotic mosaic virus, the human polyomavirus JC virus, 
the Hibiscus chlorotic ringspot virus, and the alphaviruses.24 
 
2.2.2 T-cells 
The T-cell is also a potential carrier for drugs across the BBB. Research has 
shown that certain T-cells activated outside the CNS have the ability to migrate across a 
healthy BBB and into the CNS. Once there, they begin natural healing processes like 
inflammation, loss of barrier properties, edema formation, and demyelination. This 
process only holds true for active T-cells, not resting one.26 The different stages of T-cell 
response once activated is shown below in Figure 8. The presence of endothelial 
intercellular adhesion molecule 1 (ICAM-1) and intercellular adhesion molecule 2 




Figure 8. The stages of typical T-cell response.  




 2.2.3 Micelles 
 
Another drug delivery method is the use of polymeric micelles. They typically are 
comprised of hydrophilic and hydrophobic monomer units. A micelle is created from an 
aggregate of surfactant molecules in an aqueous solution. They form a hydrophilic 
“head” that is in contact with the outside solution, and a hydrophobic “core”. Some 
specific conditions must be met for the micelle to form. Factors like surfactant 
concentration, temperature, pH, and ionic strength contribute to the formation of the 
micelle. The critical micelle concentration (CMC) is the concentration of surfactants 
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necessary for the micelles to start forming. In addition, the critical micelle temperature 
must be met as well.28 The strength of micelle drug delivery is their ability to carry drugs 
with poor solubility. The micelles act as a vehicle by encapsulating the low solubility 
drug into its hydrophobic core. The core-drug reaction is stable.29 This allows the 
micelles to ferry the drug across the BBB. 
 
Figure 9. The cross-section view of a micelle. The drug is typically encapsulated in the 
middle cavities. 
Progress in Molecular Biology and Translational Science, 
http://www.sciencedirect.com/science/article/pii/B9780124160200000061. 
 
  2.2.4 Solid Lipid Nanoparticles 
The development of genetic engineering techniques in recent times has led to an 
increasing number of protein complexes on the market. The extensive knowledge known 
about protein structure and function has furthered this growth. One of the most common 
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and useful methods of drug delivery include SLNs. SLNs consist of a spherical, solid, 
lipid core, stabilized by surfactants and ranging from sizes 1 to 1000 nm.30 They use 
biological pathways to deliver their load to their target destinations.31 This transportation 
includes carriage within and past the BBB. The lipids attached can range from 
triglycerides, diglycerides, monoglycerides, waxes, fatty acids, and steroids.30  
 
Figure 10. The structure of solid lipid nanoparticles. The phospholipid bilayer serves as a 
carrier for the encapsulated drugs. 
The AAPS Journal, http://link.springer.com/article/10.1208%2Faapsj0902019. 
 
             SLNs also offer some unique qualities that make them preferable to other drug 
delivery methods. Drug stability, ability to carry lipophilic and hydrophilic drugs, 
possibility of controlled drug release, long-term storage, and potential large-scale 
production are some of the advantages. In addition, their well-known ingredients are 
already approved for pharmaceutical use—they are generally accepted as safe to use.30 
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Furthermore, their general flexibility and ability to be manipulated are some of the 
qualities that make them the strongest candidate for drug delivery. The spherical shape of 
the nanoparticle contributes to its general stability. SLNs can be engineered with three 
common hydrophobic core designs: a homogenous matrix, a drug-enriched core, or a 
drug-enriched surface.31 Even within the realm of nanoparticles, some are better for drug 
delivery than others. For example, enhanced physical stability and decreased degradation 
of the drug are qualities in SLNs that aren’t shared by polymeric nanoparticles.22 SLNs 
also mitigate the effects of drug resistance. Drug resistance is a property of cells that 
impedes the efficacy of molecularly targeted and conventional chemotherapeutic agents. 
Specifically, P-glycoprotein prevents the accumulation of most drug delivery vessels—
however, it is known that nanoparticles have the ability to accumulate without the 
resistance of P-glycoprotein.32 
             There are two major methods for producing SLNs, including (1) a high-pressure 
homogenization technique by Müller and Lucks and (2) a microemulsion technique 
developed by Gasco.31 The emulsion technique involves distributing the monomer in 
aqueous solution, as a uniform emulsion. The surfactants cause emulsification by 
decreasing surface tension at the monomer-water surface. This persists until the CMC is 
achieved. The CMC is the concentration in which the surfactants become part of a 
molecular aggregate.33 To sterilize the SLNs, stearic acid-PEG 2000 is generally accepted 
as the standard.34 
             SLNs have proven to be successful as a delivery method in the past.22 For 
example, cationic bovine serum albumin (CBSA) has been known to enter the BBB 
without compromising its integrity.35 Use of nanoparticles as a drug delivery method is 
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not limited to just transportation across the BBB. In a study done by Kwangjae Cho et al., 
drug-carrying nanoparticles were used to target cancerous tumor cells. They targeted the 
unique pathophysiology of tumors, some of the traits include enhanced permeability and 
retention effect and the tumor microenvironment.32 In October 2003, Hiroshi Fukui and 
his associates conducted an experiment involving amphotericin-B and drug delivery 
through the liver. They used lipid nano-spheres, a small-particle lipid emulsion. The drug 
uptake was compared to that of using Fungizone, the traditional intravenous dosage form 
of amphotericin-B. The lipid nano-spheres performed favorably against the benchmark.36 
Another study favoring the continued research of SLNs as a drug delivery method was 
conducted by Yong Hee Yu and associates at the College of Pharmacy and Research 
Institute of Pharmaceutical Sciences in Seoul, South Korea. Specifically, they formed 
CSLNs for co-delivery of paclitaxel and siRNA to tumors in mice. 1,2-Dioleoyl-sn-
glycero-3-ethylphosphocholine-based CSLN were prepared through emulsification 
techniques. Their research concluded that CSLNs were strong candidates for co-delivery 
systems of various anti-cancer drugs and therapeutic siRNAs.37  
 
Figure 11. The structure of co-delivery of paclitaxel and siRNA, as performed by Yong 
Hee Yu and associates. 




A study done in January, 2012 also supported the use of SLNs as a viable form of 
drug delivery. In a study done by Montenegro, L. et al., an antioxidant agent Idebenone 
(IDE) was loaded into SLNs across an in vivo MDCKII-MDR1 cell monolayer, which 
emulates the cell interactions of the BBB. It was discovered that IDE loaded into these 
nanoparticles permeated the cells far more effectively than free IDE. Montenegro and his 
team concluded that the future of SLNs for use as a drug delivery method was 
“promising.”38  
             Our method of drug delivery involves forming a drug delivery complex based 
upon the biotin-streptavidin bond. It is known as one of the strongest noncovalent bonds 
in nature, having a dissociation constant, Kd, in the order of 4×10−14 M. Because of this, it 
is one of the most commonly used bonds in molecular, immunological, and cellular 
assays.39 The biotin-streptavidin bond is essential for the stability of our proposed drug 
delivery model. Without it, the CSLN and anti-VCAM-1 would attach to become a 
complex. The nanoparticle is essential as a vessel for the drug, and the anti-VCAM-1 
provides a targeting system for our vehicle.  
 
2.3 Targeting Molecules 
Among the many molecules on the surface of the BBB, cell surface adhesion 
molecules exist to bind other cells to the BBB surface.40,41 Because the BBB has low 
permeability and high resistance for the brain’s protection, the cell surface adhesion 
molecules on the BBB are highly specialized and selective in which molecules they bind 
to.40,42 They are transmembrane proteins that have an intracellular domain for 
cytoskeleton interaction, a transmembrane domain, and an extracellular domain for 
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binding of other molecules.43 Their placement on the BBB is indicated below in Figure 
12. 
 
Figure 12. Cell surface adhesion molecules indicated by yellow arrows on BBB diagram. 
Febs Letters, http://www.sciencedirect.com/science/article/pii/S001457931100336X. 
 
In addition to binding to extracellular molecules, most cell surface adhesion 
molecules allow for the migration of the molecules (i.e. nutrients, immune cells, and 
various communicative molecules) through the BBB.43,44 Thus, cell surface adhesion 
molecules are valuable as targets for the delivery of drugs specifically through the BBB.45 
In diseased states, the vascular endothelium of the BBB plays a large role in the process 
of inflammation.45 ICAMs are surface adhesion molecules in the endothelium and have 
an essential role in inflammation processes.43 ICAM-1, in particular, is up-regulated by 
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TNF-α, a molecule that induces inflammation of the BBB.46 Thus, when there is 
inflammation, there is an increase in ICAM-1 because they facilitate the transmigration 
of leukocytes to reduce the inflammation.27,43 
 
Figure 13. The three dimensional protein structure of ICAM-1.  
Biochemical Journal, http://www.biochemj.org/bj/351/0079/bj3510079.htm. 
 
VCAM-1 is also a cell adhesion molecule that acts similarly to ICAM-1.47-49 
VCAM-1 is a transmembrane glycoprotein that has the ability to internalize and 
transmigrate other molecules through the endothelial layer of the BBB once the 
molecules are bound to it.45,50 VCAM-1 is similar to ICAM-1 in that it is up-regulated by 
TNF-α and the molecule itself is not a health risk for humans regardless of the 
concentration levels in blood plasma.51,52 VCAM-1 specifically has been known to 
enhance the adhesion of monocytes, a critical player in the immune system, to the ECs 
that it is expressed in, further confirming that it is involved in recovering diseased organ 
states.53 In order to adhere to uptake molecules such as monocytes, the internalized 
molecule must have a specific, complementary antibody that matches VCAM-1.54,55 
Thus, anti-VCAM-1 has been proven to be the perfect complementary antibody to 
VCAM-1 on the BBB.54,56 The vehicle and anti-VCAM-1 complex results in becoming a 
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great means of drug delivery specific to the increased amount of present VCAM-1 in 
diseased states of the BBB.54,57 Since using ICAM-1 has been well observed as a 
targeting method, we decided to use VCAM-1 as our cell adhesion molecule to better 
understand its role in BBB transmigration. 
 





3. Blood Brain Barrier 
3.1 BBB Background 
3.1.1 BBB Architecture 
The BBB is the membranous, physical separation of the circulatory system from 
the CNS in an organism. Specifically, cerebrovascular ECs lining the thin capillaries 
separate the blood and brain interstitial fluid (ISF), the choroid plexus structure that 
produces cerebrospinal fluid (CSF), and the protective meningeal arachnoid epithelium of 
the spinal cord.58,59 Closely associated with the ECs of the BBB are astrocytes, pericytes, 
and the extracellular matrix, specifically the basal lamina.6,58,60 The several cell types 
associated together compose structured NVUs, which are involved in the regulation of 
blood to and from the brain, as shown in Figure 15 below.3,58,61 
 
Figure 15. Architecture of the BBB. The interactions between brain endothelial cells, 
astrocytes, pericytes, the basal lamina, and microglia create the neurovascular units. 




The surface area of these NVUs in the brain is large (nearly 20m2 per 1.3kg of 
brain), but the tight association between the cells allows the BBB endothelium to highly 
regulate the microenvironment.58 A distinct feature of the BBB is the lack of leakage and 
restrictive permeability both to and from the brain. This restrictive membrane between 
the brain and blood was initially conceived from experiments in the late 19th and first half 
of the 20th century.62  There appeared to be an apparent barrier that would prevent the 
transport of solutes to the brain ISF. The capillary endothelium was thought to be a 
contributing factor to this selective permeability.62 Acidic and basic dyes were injected 
into the bloodstream of a patient, and observations showed a lack of penetration into 
brain tissue.  Additional studies showed that this was not due to lack of uptake by 
individual neurons, but instead due to a physical barrier that separated the peripheral 
circulation from central circulation.3,59 The dyes, when in circulation, bound to albumin 
proteins, and these proteins were unable to traverse the barrier separating the blood and 
the brain. Peripheral vessels in other parts of the body were found to be permeable to 
many types of solutes, including water-soluble compounds, through the presence of pores 
within the endothelium membrane. Horseradish peroxidase was used as an enzymatic 
tracer to localize these pores in different types of endothelium (skeletal, cardiac, and 
cerebral). The metabolized product accumulated greatly, creating an opaque center of 
activity upon visualization.62 The peroxidase product appeared to be unable to pass 
through to the brain interstitium, and instead accumulated within the intercellular 
spaces.62 The peroxidase product appeared within the brain fluid only when injected 
directly into the interstitium. Direct injection of dyes in the CSF showed clear staining, 
and additional quantitative experiments confirmed the existence of a physical barrier. 
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There are distinct differences between brain ECs and other ECs found in an 
organism: cerebrovascular cells have 1) fewer fenestrations (pore-like openings) between 
ECs, allowing for less diffusion, 2) more TJ proteins, 3) less pinocytic vesicular transport 
and hydrophilic compound diffusion, and 4) a higher number of mitochondria associated 
with strong metabolic activity.3,6,61 
The main contributors to the strong regulation of substances across the membrane 
are TJs. TJs are proteins linking the cytoskeletons of adjacent ECs and that exclude 
many, if not most, substances in the blood from reaching the brain, and establish the 
barrier properties of the BBB.6,60 TJs contain six subunits and appear as fusions of the 
plasma membrane of adjacent ECs.6,60 Many regulatory signaling pathways exist, which 
include G-proteins, serine-, threonine-, and tyrosine-kinases, cAMP, and others.60 TJs are 
primarily composed of three integral membrane proteins, specifically occludin, claudin, 
and JAMs.   
Occludin was initially identified through freeze fracture microscopy in chickens 
and mammals.6 Occludin proteins highlight a molecular difference between brain and 
other ECs, in that occludin expression is greater in brain ECs. Specifically, the 
cytoplasmic side of the occludin is heavily phosphorylated in TJs, and acts as a 
regulatory protein to affect membrane permeability.6,58,60,61 Claudins are another family 
of proteins within TJs that affect membrane permeability. Specifically, claudin-1 and 
claudin-5 have been isolated in cerebrovascular endothelial cell tight junctions, and 
current speculation indicates claudin-12 to have some contribution.58, 60 Claudins 
associate with occludins to form and maintain TJ integrity.58 JAMs are also proteins 
present within TJs, have a single transmembrane domain, and serve to form and maintain 
 31 
TJ structure.6 There are several types of JAMs that are found in specific cell types: JAM-
1 is found in endothelial and epithelial cells; JAM-2 and JAM-3 are found in mainly 
endothelial and not epithelial cells.60 JAMs serve to regulate interactions at the TJ area. In 
addition to the three main protein families described above, there are other accessory 
proteins that compose TJs, such as zonula occludin proteins that face the cytoplasmic 
side.  Another important molecule, while not considered to be one of the three primary 
integral TJ proteins, is the protein β-catenin.  In the context of the BBB, it anchors the 
cytoskeleton of adjacent ECs to strengthen their junctions and decrease permeability, and 
also plays a role in signaling cascades that lead to angiogenesis during BBB formation as 
well as maintenance of the mature BBB.63,64   
 
3.1.2 BBB Differentiation 
 
Figure 16. In vivo imaging of a neurovascular unit (NVU). A) Electron microscopy 
image of a NVU. B) Confocal microscopy of a rat brain NVU, with green fluorescence 
marking endothelial cells, and red fluorescence indicating astrocytes.    
Science Direct, http://www.sciencedirect.com/science/article/pii/S0005273608003489 
BBB selective permeability characteristics, such as the presence of TJs, are 
inherent to the ECs, but the differentiation of the membrane barrier is linked to the 
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remaining components of the NVU: astrocytes, pericytes, and the basal lamina, shown 
below in Figure 17.  The close associations between individual components allows for 
induction of new cell growth during both during development and after maturity, for 
maintenance purposes. While the traditional and most researched relationship is the 
induction of the growth of ECs by astrocytes, pericytes, and the basal lamina, studies 
have shown that the ECs themselves can, in turn, induce the growth of these cells, in 
particular astrocytes.58 There is a constant “cross-talk” within the NVU that allows for 
BBB growth induction and function.3  
 
Figure 17. Composition of the differentiated BBB on a cellular level. Not the multiple 
cell types involved in the creation of the BBB.  
Nature Reviews Neuroscience, 
http://www.nature.com/nrn/journal/v7/n1/fig_tab/nrn1824_F5.html 
 
Astrocytes are considered to be the major contributor to BBB differentiation, as 
their ends are associated directly with the cerebrovascular ECs.65 Astrocytes descend 
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from the ependymoglia of the neural tube, and are polarized cells whose ends are directly 
associated with the cerebroendothelial cells. Astrocytes secrete several substances, 
including transforming growth factor-β (TGF-β), glial-derived neurotrophic factor 
(GDNF), fibroblast growth factor (FGF), and angiopoietin-1 (ANG-1)58.  TGF-β and 
GDNF have been found to mature the BBB postnatally.6 These several factors can induce 
BBB differentiation in vivo, including the formation of TJs.60 Studies have shown that the 
implantation of cultured astrocytes into areas with a leaky endothelium induced 
tightening of the endothelium.6 Co-culture of brain ECs with astrocytes has also shown 
the inductive effects of the latter, with BBB properties illustrated in culture.61 Astrocytes 
maintain and up-regulate existing BBB features, such as expression of transport proteins 
and presence of enzyme systems.58 One particular study injected astrocytes into the eye 
chamber of adult rats, and within 48 hours, those cells became vascularized. Dyes were 
injected into the same chamber, and aggregates of cells that were not associated with 
astrocytes were highly stained with the dye, but aggregates of cells that were associated 
with the astrocytes were not stained. The ECs that formed capillaries had functioning TJs, 
while others were much more leaky.65  
Pericytes are embedded within the basal lamina that is adjacent to the ECs. 
Pericytes wrap around the ECs to provide structural support, assist in vasoregulation, 
restrict permeability, and assist in the differentiation of the ECs and TJs.6,58,61 Pericytes 
are the least studied component of the NVU, but research has shown that these cells assist 
in BBB function in vivo by regulating BBB-specific gene expression patterns and by 
inducing polarization in the ends of astrocytes that surround the blood vessels in the 
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CNS.61,66 While more is to be discovered and understood, it is clear that pericytes play a 
direct role in the stability of the BBB.   
The basal lamina is a complex network of consisting of collagens, including 
laminin, fibronectin, enactin, thrombospondin, and proteoglycans.60,61 There are three 
main layers, one produced by the ECs, one produced by the astrocytes, and one in which 
both cell types contribute. It works in tandem with the other components of the NVU to 
maintain BBB properties and function, specifically BBB integrity.61 Specifically, the 
basal lamina contains agrin, a heparin sulfate proteoglycan, which accumulates during 
initial BBB formation, and works to sustain BBB integrity.58  
 
3.1.3 BBB Permeability  
            The ISF within the brain has a different ion concentration from the rest of the 
body, and this ion concentration is independently maintained through BBB 
mechanisms.13 The BBB produces a physical barrier primarily through the presence of 
restrictive TJs between ECs, which forces molecules to take a transcellular route.58 Small 
gaseous molecules such as O2 and CO2 can diffuse freely through lipid membranes, as 
well as small lipophilic molecules, but the remaining polar (and semi-lipophilic) and 
large compounds are generally impermeable. 6,58 The BBB additionally produces a 
metabolic barrier through intracellular and extracellular enzymes, which include 
peptidases, nucleotidases, monoamine oxidases that are used to metabolize substrates. 
This property of the barrier can breakdown or inactivate many compounds and toxins.58  
             The main methods of BBB transversal are receptor-mediated entry and 
adsorptive-mediated transcytosis. Insulin and transferrin use receptor-mediated 
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transcytosis to cross the BBB, and glucose uses the GLUT-1 insulin independent carrier. 
Adsorptive-mediated transcytosis, which requires the interaction of the ligand to 
membrane surface charges before internalization, is most frequently utilized by cationic 
molecules.58,67,68 Amino acids, nucleobases, and nucleosides use their own individual, 
specific carriers.58,61 The large family of solute carrier transporters (SLC) contributes to 
many transport mechanisms.61 Immune cells, such as leukocytes, traverse the BBB 
through adhesion molecules, such as ICAM-1, VCAM-1, PECAM-1, and CD44.6,61 
            TEER has additionally been associated with the selective permeability of the 
BBB. In general, a higher TEER value (measured in Ohms) is associated with a low 
paracellular permeability, and therefore a tighter and more selective membrane.69 
Researchers have measured the TEER values in developing rats through the use of 
lanthanum (a chemical element) and electron microscopy. The resistance was measured 
in pial vessels in fetal rats between 17 and 21 days of gestation, in 1 to 10 day neonates, 
and 28 to 33 day old rats.13 There was a significant increase in TEER from 20 to 21 days 
gestation (323Ω to 1128Ω), with no significant increase after that period. Lanthanum 
appeared to accumulate on the apical side of TJs, and did not appear to traverse to the 
brain interstitium, as the mature and functioning BBB does not allow the passage of this 
element to the brain.13 Pathological conditions were also observed to illustrate the 
importance of high TEER values to maintain a homeostatic environment. During 
hyperosmotic shock, when there is a significant increase in permeability, TEER values 
measured were significantly lowered. Similar conclusions were made with in vitro 
monolayers of ECs, with higher TEER values associated with tighter and more confluent 
monolayers.70 Many studies have been performed to better understand the effects of 
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particular molecules, such as malathion, malaoxon, cAMP, and vasoactive agonists on 
the TEER values of in vitro BBBs.71,72 High TEER values in vitro also occurred in BBB 
models that were associated with cultured astrocytes.6 
 
3.1.4 BBB Pathology 
Neural diseases have a variety of implications for the integrity of the BBB. 
Generally, there tends to be a change in permeability of the membrane that causes drastic 
movement of substances. Physiological manifestations are inflammation, edema, and 
breakdown of tissue.6,58,61 While neural diseases may affect the integrity of the BBB, loss 
of healthy BBB function may conversely result in the worsening or development of 
neurological diseases.  These include acute and chronic cerebral ischemia, multiple 
sclerosis, brain tumors, and Alzheimer’s disease.73 An important reason for the BBB 
dysfunction or breakdown is due to malfunctioning TJs between ECs, which allow 
passage of molecules within the gaps between ECs.58 Claudins within the TJs are lost or 
down-regulated in diseased states, leading to the breakdown of TJs.6 
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Figure 18. Various cytokines associated with pathological conditions and the BBB. 
Histamine and TNF-α, among other inflammatory signals, are released during 
inflammation of the BBB.  
Nature Reviews Neuroscience, 
http://www.nature.com/nrn/journal/v7/n1/fig_tab/nrn1824_F6.html 
 
Other chemical mediators released during neural diseased states alter BBB 
structure and permeability. Histamine, a major inflammatory chemical, allows for the 
passage of antibodies into the brain.58 Histamine can be released in conjunction with 
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TNF-α, interferon γ, nitric oxide, and several other mediators, which also act to decrease 
BBB permeability, as shown in Figure 18.6,58,61 TNF-α has also shown to rearrange the 
cytoskeleton of the cell through its cytokine effects.3 The BBB tries to counteract 
permeability changes with the support of the components of the NVU, especially 
astrocytes and other microglia, by limiting TJ protein destruction.6 However, this support 
is at the early stages, and is overpowered as diseases progress.  
Changes in the BBB and associated components of the NVU depend upon the 
specific disease. In Alzheimer’s, the accumulation of amyloid-β proteins is initially 
observed in the blood vessels, and this accumulation causes the degradation or 
impairment of adjacent astrocytes and ECs of the NVU.58 Additionally, the loss of agrin 
from the basal lamina adjacent to ECs can cause BBB damage and weakness.58 This 
physiological symptom preceded other clinical symptoms of neurological decline in 
Alzheimer’s animal models. Cascades of cellular events are signaled, which exacerbates 
the ongoing damage, specifically affecting neuronal integrity and synaptic function.6,61 
Alzheimer’s, HIV, and multiple sclerosis become progressively worse after BBB 
dysfunction due to the infiltration of immune cells into the brain, which additionally 
triggers inflammatory effects through cellular cascades. TJ proteins are degraded further.6 
In certain cancers, such as gliomas and adenocarcinomas, TJs begin to open, which leads 
to similar brain infiltration.6 Cytokines were also elevated in animal models after local 
and global ischemia, and in stroke, which can also enhance ischemic injury. 6,61 Bacterial 
infections also enhance cytokine production and other inflammatory mediators to 
increase BBB permeability.61  
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The relationship between disease onset, disease progression, and BBB changes is 
very complex, yet its understanding and exploitation is crucial to developing safe and 
successful treatment modalities.  There have been numerous explorations into drug-
delivery devices, but of particular interest are those that directly target the BBB 
endothelium.  
 
3.1.5 BBB Targeting 
BBB damage often precedes the major physiological consequences of disease, 
which is why it is becoming a prominent area of research in relation to a drug-delivery 
target.58 Through early targeting and treatment of the BBB, it may be possible to reduce 
the progression of a disease or the severity of symptoms. There are additional hopes for a 
prophylactic treatment of the BBB to delay the onset of a disease.58 During diseased 
states, the release of cytokines causes the up-regulation of numerous cellular adhesion 
molecules and receptors on the BBB through a cascade of signaling. The entry of 
leukocytes and other immune cells into the BBB is a multi-step process: there is the 
initial immediate contact of the immune cell to the BBB membrane, followed by the 
cessation of rolling across the surface, followed by adhesion to the membrane through 
receptor binding, and then finally passage through the membrane to the brain.3 
Leukocytes gain entry to the brain by binding to adhesion molecules on the endothelium, 
specifically ICAM-1, VCAM-1, E-selectin, and recently-identified activated leukocyte 
cell adhesion molecule (ALCAM).61 It is thought that cell adhesion molecules work 
together with one another to increase leukocyte transmission into the brain to fight 
infections.61 ICAM-1 is particular for both leukocytes and lymphocytes, and is both a 
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passive adhesion site and traversal site for immune cells through the activation of cellular 
cascades.60 Because of its up-regulation in the BBB endothelium during diseased states, it 
has been investigated as a potential target for novel treatment models.41,74,75 VCAM-1 is 
typically expressed in minute quantities, in the vascular endothelium.  When cytokines 
cause the up-regulation of VCAM-1 expression, lymphocytes, monocytes, eosinophils, 
and basophils are able to adhere and interact with normal and diseased vasculature states.  
For example, up-regulation of VCAM-1 has been shown to play a role in the 
development of atherosclerosis, as well as other inflammatory diseases such as multiple 
sclerosis.76,77   
As discussed in the literature review section above, there have been various 
targeting methods investigated in the past.  This project aims to use the natural up-
regulation of VCAM-1 expression on the BBB endothelial membrane during diseased 
states as the target of a CSLN drug delivery complex. 
 
3.1.6 Project Aims 
            While the overall aim of this project is to develop a novel drug delivery complex 
to traverse an in vitro BBB model, this section of the project is focused on the 
development and characterization of the BBB model.  The methodology below will 
discuss cell culture methods and techniques, model formation, proof of model formation 
through staining of TJ proteins, characterization of VCAM-1 expression as TNF-α 
concentration varies, and lastly, quantification of fluorescent bead migration through the 
BBB model. 
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3.2 BBB Methodology 
3.2.1 Human Brain Microvascular Endothelial Cell Culture 
The primary HBMECs were purchased from Applied Cell Biology Research 
Institute (ACBRI 376). The HBMEC medium was made using the following reagents: 
Roswell Park Memorial Institute (RPMI) media, fetal bovine serum (FBS), L-glutamine, 
EC growth supplement (ECGS), heparin, and penicillin/streptomycin. The RPMI media 
was stored at 4oC and the other supplements and antibiotics were stored at -20oC. In order 
to make one batch of medium with a final volume of 500 mL, 370 mL of RPMI media 
was used. One hundred mL of 100% FBS was used, yielding a final concentration of 20% 
FBS. 5 mL of a stock solution of 200 mM L-glutamine was added, making the final 
concentration 2 mM L-glutamine. 15 mL of 1 mg/mL ECGS was used in order to give a 
final concentration of 30 µg/mL ECGS. 5 mL of 10 mg/mL heparin was added to the 
solution, giving a final concentration of 100 µg/mL heparin. Finally, 5 mL of the 
penicillin/streptomycin stock solution (10,000 U/mL and 10 mg/mL respectively), 
yielding a final concentration of 100 U/mL penicillin and 100 µg/mL streptomycin. This 




 Stock Final (in 500 mL) Volume to 
make 500 
mL 
RPMI Media   370 mL 




1 mg/mL 30 µg/mL 15 mL 
Heparin 10 mg/mL 100 µg/mL 5 mL 
Penicillin/streptomycin  10,000 U/mL (pen) 
10 mg/mL (strep) 
100 U/mL (pen)  
100 µg/mL (strep) 
5 mL 
Table 1. Recipe for HBMEC Media 
            The media for the HUVECs was made according to Table 2. The basal medium 
was stored at 4oC and the supplements and penicillin/streptomycin were stored at -20oC. 
After the media was prepared it was stored at 4oC. HUVEC media was used within 2-3 
weeks after it was made. The volumes of the reagents were adjusted if more or less media 




 Final (in 500 
mL) 
Basal Media 461 mL 
EnGS 1 mL 
Rh EGF 500 µl 




Heparin Sulfate 500 µl 
FBS 10 mL 
L-glutamine 25 mL 
Penicillin/ 
Streptomycin  
1 mL  
Table 2. Recipe for HUVEC media.  
 
3.2.2 Procedure for Changing Media 
             The media was placed in the 37°C water bath for 30 minutes until it was warm. 
In the cell culture hood, the media in the flask containing the cells was aspirated out 
using a glass pipette. 5 mL of fresh HBMEC media was added to a T-25 flask, or 10 mL 
for a T-75 flask. The media was changed every other day during the week. Every 
Monday and Wednesday, 5 mL of media was added to a T-25 and 7 mL of media was 
added on Friday to account for the weekend. For the T-75 flasks, 10 mL of media was 
added every Monday and 12 mL of media was added on Friday. After fresh media was 
added, the flask containing the cells was placed back in the incubator. The cells were 
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grown in a humidified incubator at 37oC and 5% CO2. The same procedure was used to 
change the media for HUVECs. The HUVECs were also grown under the same incubator 
conditions.  
 
3.2.3 Procedure for Splitting Confluent Cells 
The following reagents were used for the cell splitting procedure: 0.01 M 
phosphate buffered saline (PBS) (pH ~7.1), 0.05% Trypsin-EDTA, and HBMEC media. 
These solutions were warmed in the 37oC water bath before they were used. The media in 
the flask containing confluent cells was aspirated out using a glass pipette. The cells in 
the flask were washed by adding 5 mL of PBS and tilting the flask around. The PBS was 
aspirated off after 10 seconds. The cells were detached from the wall of the flask by 
adding 750 µl of trypsin-EDTA. The flask was tilted around to expose the cells and then 
incubated at 37oC for 2 minutes. The flask was observed under a light microscope to 
ensure that the cells were spherical in shape and floating in the liquid. The trypsin was 
diluted by adding 5 mL of media to the flask. The solution was then transferred to a 15 
mL conical tube and centrifuged for 5 minutes at 5oC and 150x g. The supernatant was 
removed, leaving a small amount of media and the cell pellet at the bottom of the tube. 
The pellet was re-suspended in 5 mL of media by pipetting up and down until no clumps 
of cells remained. The cells were counted by adding 10 µl of the cell-media solution to a 
hemacytometer. The number of cells were counted in each corner grid and then averaged. 
This number was multiplied by 104 to give the concentration in cells/mL.  A fresh flask 
was filled with 5 mL of media. The number of cells added to the new flask depended on 
how fast the cells were needed to be confluent, as seen in Table 3. The volumes of 
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solutions used in this procedure were for a T-25 flask. If a T-75 flask is used, double all 
volumes in the protocol. This procedure was used for splitting both HBMECs and 
HUVECs. 
 T-75 T-25 
Confluent  6.0E+06 3.0E+06 
1 Day 3.0E+06 1.5E+06 
2 Days 1.5E+06 7.5E+05 
3 Days 7.5E+05 3.8E+05 
4 Days 3.8E+05 1.9E+05 
5 Days 1.9E+05 9.4E+04 
Do not place less than  1.0E+05 5.0E+04 
Table 3. Confluency Table. The number of cells to add to the flask based on when 
confluency is desired 
 
3.2.4 Thawing HBMECs 
            5 mL of media was added to a T-25 flask. The flask was placed in the incubator 
for 30 minutes to warm up the media. To start a new line of HBMECs, a vial of cells was 
removed from the liquid nitrogen tank and placed in the 37oC degree water bath. The vial 
was thawed for 1-2 minutes. When the cells were completely thawed, the entire 1 mL 
contents of the vial were added to the flask with the warmed media. The flask was placed 
in the incubator and the media was changed after 24 hours to remove any unattached 
cells. From this point, the cells were maintained with normal cell culture techniques. The 
HBMECs were used through passage 9, but not past passage 12.   
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3.2.5 Making the BBB Model: Monolayer of Cells on Glass Coverslips 
Fibronectin was added to a 22 x 22 mm coverslip for the cells to attach to the 
surface of the glass coverslip. The coverslips were washed with PBS. A coverslip was 
added to each well of a 6-well plate. The dish was put under the UV for 1-2 hours. A 300 
µl fibronectin solution (100 µg/mL) was added to each coverslip. The solution was made 
using 270 µl 1X PBS and 30 µl 1 mg/mL fibronectin. The 6-well plate was tilted to 
spread the solution evenly across the coverslip and left in the hood for 2 hours. After 2 
hours the cells were split on to the coverslip. In order to make a monolayer of cells in 2-3 
days, 4x105 cells were split onto each coverslip.  
 
3.2.6 Adding TNF-α 
TNF-α is a cytokine that induces the inflammatory response in cells. It was added 
in varying concentrations to the monolayer of cells to simulate different diseased states. 
As the concentration of TNF-α increased, the cells simulated a more diseased state, 
therefore there we expected to observe an up-regulation of VCAM-1. The TNF-α was 
added to the monolayer of cells 18 hours prior to experiments that were conducted. The 
following concentrations were used for all experiments: 0 mg/mL, 2 mg/mL, and 20 
mg/mL. 6 coverslips total were used for every experiment with 2 coverslips per 
concentration. Once the TNF-α was added, the monolayers of cells were placed back into 





3.2.7 Immunofluorescent Staining for VCAM-1 
The cells incubated in TNF-α for 18 hours were fixed in order to stop them from 
growing. They were fixed in 2 mL of 2% paraformaldehyde for 20 minutes. The fixation 
step was done in the dark since paraformaldehyde is light sensitive. The cells were 
washed twice in 2 mL of PBS of for 5 minutes on a rocker to ensure uniform distribution 
of the PBS. After the washes, 2 mL of 2% BSA in PBS were added to each well to block 
nonspecific binding. The cells were blocked in the 2% BSA for 2 hours at room 
temperature. The blocking buffer was removed and 200 µl of primary anti-rabbit VCAM-
1 antibody was added to each coverslip. The final concentration of the primary antibody 
was 10 µg/mL. The cells were incubated in primary antibody for 1 hour. After an hour, 
the cells were washed with PBS twice for 5 minutes each. The cells were blocked again 
with 2% BSA in PBS for an hour. The blocking buffer was removed and 200 µl of 
secondary goat anti-rabbit antibody was added to each coverslip. The final concentration 
of the secondary antibody was 5 µg/mL. The cells were incubated in secondary antibody 
for 1 hour. After an hour, the cells were washed with PBS twice for 5 minutes each. The 
nucleus was then stained with a Hoechst stain. 200 µl of the Hoechst stain diluted to 2 
µg/mL was added to each coverslip for 20 minutes. After an hour, the cells were washed 
with PBS twice for 5 minutes each. The cells were then viewed under the microscope to 
take images. The cells were viewed under light using a DIC filter. To view the stained 
nucleus, the cells were viewed using the DAPI filter. The VCAM-1 was viewed under the 




3.2.8 Bead Experiments 
Fluorescent microspheres (or beads) from Invitrogen were used as controls to test 
whether or not any materials could get through the BBB. These beads are polystyrene 
microspheres that have been modified with carboxylates on their surface.  The 
fluorescent dyes added have been stated to have negligible effects on the properties and 
interactions of these beads.  The purpose of using the fluorescent microspheres was to 
ensure that the nanoparticle complex that was synthesized would be able to be tested on 
the model. First, the microspheres alone were tested on monolayers of cells that had been 
incubated with different concentrations of TNF-α for 18 hours as mentioned in Section 
3.2.6. 25 µl of fluorescent microspheres were added to the cells. After an hour, the 
microspheres were washed off of 1 set of cells (0 µg/mL, 2 µg/mL, and 20 µg/mL TNF-
α) and were imaged under the microscope. Images using phase microscopy were taken at 
an exposure of 100 milliseconds. Images of the fluorescent microspheres were taken 
using the TRIT-C filter at an exposure of 10 milliseconds. The microspheres were 
washed off the other set of cells after 5 hours and were imaged under the same 
conditions.  
This experiment was also repeated but VCAM-1 antibody was added to the 
HUVECs to block VCAM-1 receptors on the surface of the cells. The primary VCAM-1 
antibody was added to monolayers of cells that were in 2 mL of media. The cells had 
been incubated with TNF-α for 18 hours prior to starting the experiment. The antibody 
was diluted in 2% BSA, giving a final concentration of 5 µg/ml. An hour after the cells 
were incubated, they were washed with HUVEC media. Then 25 µL of the fluorescent 
microspheres were added to each monolayer of HUVECs.  After an hour, the 
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microspheres were washed off of one set of cells (0 µg/mL, 2 µg/mL, and 20 µg/mL 
TNF-α) and were imaged under the microscope. Images using phase microscopy were 
taken, with an exposure of 100 milliseconds and images of the fluorescent microspheres 
were taken using the TRIT-C filter with an exposure of 10 ms. The microspheres were 
washed off the other set of cells after 5 hours and were imaged under the same 
conditions. 
Images were analyzed using the ImageJ processing program developed by the 
National Institute of Health (NIH). Both phase microscopy and fluorescence images were 
analyzed to count the concentration of fluorescence in the different staining and bead 
experiments. The data was then normalized if possible to counter the varying levels of 
noise in the background of images.   
 
3.2.9 Imaging Techniques 
Images were analyzed using the ImageJ processing program developed by the 
NIH as well as MATLAB developed by Mathworks. Fluorescence images were analyzed 
to quantify the concentration of fluorescence in the different staining and bead 
experiments. This was achieved in two ways. For single images, ImageJ’s histogram 
feature was used to observe distribution and mean fluorescent intensities. ImageJ was 
also used for the cell counter tool when nucleus stains were available. When multiple 
images were averaged to create a histogram and/or when a modified histogram was 
needed, images were imported into MATLAB. The data was then normalized if possible 
to counter the varying levels of noise in the background of images. 
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ImageJ’s histogram feature was the most basic way to quantify fluorescence. For 
a single image, it gives both a mean fluorescent intensity of the image as well as 
quantitative and visual representations of the intensity distribution. The histogram tool is 
found under the “Analyze” menu. One of the benefits of using the histogram tool is that it 
gives lots of quantitative information about the image. An important piece is Minimum 
Value; as the minimum value is representative of background noise in the image, 
sometimes it is valuable to subtract the background using ImageJ’s subtract function 
(under “Process” à”Math” à “Subtract…”) so that all images are on equal footing. This 
is one form of normalization available. The other form is normalizing to the number of 
cells in the sample. When nucleus stains are present, ImageJ’s Cell Counter (as seen 
below) is used. It can be found under “Plugins”à”Analyze”à”Cell Counter.” 
In MATLAB, the histogram functionality was available through the use of the 
“histc” function. The function takes a vector and returns the frequency of values in the 
vector. To determine the frequency across multiple samples, images were reshaped into 
vectors in MATLAB and concatenated together before being passed to the histc function. 
To differentiate the histograms from those in ImageJ, any post-processing steps can 
applied to the output of histc. The one we are interested in is taking the logarithm of the 
output frequencies to better visualize distributions when compared to ImageJ histograms. 






3.3 BBB Data and Results 
3.3.1 HBMEC VCAM-1 Staining 
The HBMECs were analyzed in ImageJ using the Cell Counter and Histogram 
functionalities to determine relative levels of fluorescence emitted by VCAM-1 staining. 
Fluorescence is correlated to VCAM-1 expression which can be compared with other 
samples. Fluorescence intensity is used to quantitatively compare samples both from the 
same experiment and other experiments. The nucleus and VCAM-1 stains were also 
combined to view localization of VCAM-1. The nucleus appears blue and VCAM-1 
appears red. For cell counting, partial nuclei are included, although partial cells are not 
counted fully. Instead, any partial cells are typically counted as half unless the nuclei are 
almost completely outside the field of view.  
 
Figure 19. Composite image created of VCAM-1 stained HBMECs incubated without 
TNF-α. Very little localization of VCAM-1 expression is seen as most of the 
fluorescence is very diffuse. The white arrow indicates blue nuclei staining, and the green 
arrow indicates VCAM-1 staining. 
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As seen above in Figure 19, VCAM-1 staining for cells incubated with 0 µg/mL 
of TNF-α show very different levels of fluorescence throughout the sample. There is no 
specific localization of VCAM-1 in the cell layer; rather, fluorescence appears in random 
fashion. The noisy image also suggests that VCAM-1 expression is fairly low, which in 
turn suggests low fluorescent intensities. However, the mean fluorescence intensity (MFI) 
of the HBMECs is 115 with 65 cells present in the image. For an 8-bit image with pixel 
values ranging from 0 to 255, the MFI falls in the middle range of pixel intensities. This 
does not necessarily follow with the previous assumption that the fluorescence is low. To 
compare the results with the other samples, the fluorescence intensity is normalized by 
the number of cells, giving a value of 1.77 MFI per cell (MPC).  
 
Figure 20. Composite image created of VCAM-1 stained HBMECs incubated with 2 
µg/mL of TNF-α. Localization of VCAM-1 expression is evident as noticeable structures 
are occurring that are not present in the sample without TNF-α. The white arrow indicates 
blue nuclei staining, and the green arrow indicates VCAM-1 staining. 
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            In the sample incubated with 2 µg/mL TNF-α, localization of VCAM-1 is readily 
apparent. VCAM-1 expression is no longer diffuse throughout the sample, as several 
regions in the image have higher levels of fluorescence unlike in the previous sample. By 
simple visual inspection, the fluorescence also appears to be greater with the inclusion of 
TNF-α, as there is less noise distorting the image. The MFI in turn is higher at 179 with 
89 cells. Once normalized, the MPC becomes 2.  Expression still looks to be fairly 
homogeneous, as most cells are expressing the receptor. There are a few cells that are not 
expressing VCAM-1 as well as some that are exhibiting low levels of expression. 
However, the overall trend shows increased expression of VCAM-1 in the presence of 
TNF-α. 
 
Figure 21. Composite image created of VCAM-1 stained HBMECs incubated with 20 
µg/mL of TNF-α. Localization of VCAM-1 expression is evident again, but there are 
more cells that are either not expressing or weakly expressing the receptor. The white 
arrow indicates blue nuclei staining, and the green arrow indicates VCAM-1 staining. 
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The superficial results of the 20µg/mL sample are similar with respect to the 
previous sample. Localization of VCAM-1 is clear, as several cells are not expressing 
any of the receptor while some are expressing it very strongly. The pattern of expression 
is different from the previous two samples though, with fewer regions of VCAM-1 
expression as well as slightly more defined boundaries of fluorescence. The images do 
not give a strong indication of the morphological changes, although some of the VCAM-
1 structures look narrower.  As a result of the different pattern, the MPC is only 116 with 
79 cells, with a corresponding normalized value of only 1.47. The normalized value is 
lower than either of the two samples, indicating that there is an overall decrease in 














Figure 22. Histograms representing the pixel intensity distributions of the three images, 
corresponding to the a) 0 µg/mL, b) 2 µg/mL, and c) 20 µg/mL samples. As the TNF-α 
concentration increases, distribution of pixel intensities widens.  
 
To look for differences beyond the mean values, the histograms are also 
compared as a way to better gauge overall VCAM-1 expression. By simply observing 
distributions, TNF-α has a clear effect on the fluorescence intensity distribution. The 
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distribution for 0 µg/mL is very narrow and centered towards the middle of all intensity 
values. Considering the noise present in the image, it is no surprise that distribution is as 
so. The distributions for when TNF-α is added are wider and represent more pixel 
intensities. The overall trend seems to be that TNF-α widens the distribution of the 
fluorescence intensity, not necessarily just the raw mean intensity. The shapes of the 
distributions are also different. When no TNF-α is present, the shape is fairly symmetric 
about the mean, whereas when TNF-α is present the shape is more positively skewed. 
Having a wider distribution is indicative of more fluorescence, as the intensity is higher 













Figure 23. Histograms representing the pixel intensity distributions of the three images, 
adjusted to normalize all three background values to 0. The histograms correspond to the 
a) 0 µg/mL, b) 2 µg/mL, and c) 20 µg/mL samples. A trend in the means is more 
apparent in the adjusted data.  
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An underlying issue in the distributions is evident from the histograms. If the 
differences in background noise are not taken into account, then there is no reasonable 
trend of VCAM-1 expression in relation to TNF-α. The minimum values, which represent 
the background, differ greatly between the 20 µg/mL sample and the other two samples. 
To correct for the discrepancy, the histograms are shifted so that the minimum values 
become 0, negating the baseline background signal in the analysis. With the baselines 
uniform, the relative fluorescence intensities can be compared without any confounding 
factors.  
Once the background is subtracted out, the MFI for the three levels of TNF-α 
correspond to 16.9, 61.872, and 72.025. Now the trend is positive correlation between 
VCAM-1 and TNF-α which is not readily apparent in the unadjusted data. The trend is 
not linear, which is unsurprising. Instead, the trend looks logarithmic. The relative 
difference between the 0 µg/mL and the 2 µg/mL is maintained since the backgrounds for 
the two samples were the same. An important note is that the difference between the two 
levels of TNF-α is not that large, despite the increase by an order of magnitude. This 
reinforces the notion that the fluorescence intensity follows a logarithmic trend for a 
linear increase in TNF-α. This indicates that small concentrations of TNF-alpha are 









              In Figure 24, we can see a clear trend in VCAM-1 expression in relation to TNF-
α. The trend is logarithmic, as there is a large increase in fluorescence from the sample 
without TNF-α to the 2 µg/mL sample. The difference between the 2 µg/mL and the 20 
µg/mL sample is comparatively smaller. The difference is less important than the 
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Figure 24. Trends of VCAM-1 expression in HBMECs in relation to TNF-α. 
The expression trend is similar to a logarithmic trend, with the highest 
concentration of TNF-α yielding the highest quantity of fluorescence. Points 
represent a single datum point.  
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3.3.2 HUVEC VCAM-1 Staining 
 
Figure 25. Composite image created of VCAM-1 stained HUVECs incubated without 
TNF-α. VCAM-1 is barely visible as it is indistinguishable from the background, much 
like in the HMBEC sample. The white arrow indicates blue nuclei staining. 
 
            The set of VCAM-1 stains on HUVEC cells was put through the same analysis 
steps as the HBMEC set. As seen in Figure 25, very little signal appears in the VCAM-1 
fluorescence. Thus expression is not any different from the background captured by the 
camera. The result is not surprising, as HUVECs are not expected to express significant 
levels of VCAM-1 without cytokine stimulation.78 The two samples taken have MFIs 
corresponding to 3.89 and 3.82 against 128 and 112 cells respectively. The result is a 
MPC of 0.03 and 0.034. Compared to HBMECs, HUVECs with no cytokine activation 
have about 1.75 orders of magnitude lower VCAM-1 expression. Unlike the HBMEC 




Figure 26. Composite image created of VCAM-1 stained HUVECs incubated with 2 
µg/mL of TNF-α. VCAM-1 expression is visible, although fluorescence is not very 
strong compared to the HBMEC sample. The white arrow indicates blue nuclei staining, 
and the green arrow indicates VCAM-1 staining. 
 
VCAM-1 expression is visible once the TNF-α is added to the samples. The same 
problem that plagues the HBMEC 0 µg/mL sample appears in the HUVEC samples 
though. The signal is weak, resulting in visible noise throughout the image. However it is 
consistent with the lower baseline VCAM-1 expression. The difference is that the 
fluorescence is distinguishable from the background noise, allowing visual confirmation 
of VCAM-1 expression. Visually, the boundaries of cells are more visible in the lower 
expression. Cell morphology is also more recognizable as the fluorescence does not seem 
to be overlapping.  
An interesting revelation from the images is that the increased fluorescence is not 
reflected by the quantitative data. The two samples have MFIs of 4.5329 and 4.4806 to 
136 and 141 cells respectively. While the mean values indicate an overall increase in 
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fluorescence, the normalized values come out to 0.033 and 0.032 which are not 
significantly different from the sample without TNF-α. The disparity between the 
measurements and the visual evidence thus is not a result of simply the normalized 
fluorescence. It is more likely due to a marginally wider distribution of fluorescence 
intensities, much like in the HBMEC samples. 
 
Figure 27. Composite image created of VCAM-1 stained HUVECs incubated with 20 
µg/mL of TNF-α. VCAM-1 expression is comparable to the previous sample and shows 
fewer regions of no expression compared to the analogous HBMEC sample. The white 
arrow indicates blue nuclei staining, and the green arrow indicates VCAM-1 staining. 
 
            Similar results are seen when the sample is incubated with 20 µg/mL TNF-α. 
Visually, VCAM-1 expression is no different from the previous sample. The same noise 
is present, indicating that the fluorescence will not be much higher than before. The 
structure of VCAM-1 is very similar, showing that cell morphology is nearly unchanged 
in the presence of TNF-α. A major difference between the HUVEC and the HBMEC 
samples is the extent of expression. In the HBMEC sample, there are some cells not 
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expressing VCAM-1, resulting in dark spots in the image. While there are still a couple 
of dark spots in the 20 µg/mL sample, the amount of space is not on par with the 
HBMEC sample. Instead, it is more similar to the 2 µg/mL sample, where there are only 
a few dark spots and also a few areas of low fluorescence intensity. 
The MFI of both samples is 4.5192, with 103 and 98 cells in each. The MFI is 
about the same as the previous sample, which reinforces the visual similarity. The MPCs 
are 0.44 and 0.46, a rise from the previous sample. VCAM-1 expression is expected to 
increase as TNF-α increases in HUVECs, which the MPC shows.79 It also shows that the 
trend in VCAM-1 expression is similar to that seen in the HBMEC sample. However, 
considering how evenly VCAM-1 expression is expressed throughout the entire sample, 
normalizing to the number of cells may not be a reasonable move. While both the MFI 
and MPC are taken into account, the MFI holds more weight, at least in the HUVEC 
samples.  
             A result of the significantly lower intensity values is the drastically narrower 
intensity distributions available. The standard histograms produced by ImageJ are not 
presented as the displayed distributions do not represent the image overall. The range of 
values displayed on the histogram needs to be reduced because of the overall lower 
intensity. Also with fewer pixels representing the higher intensities, a standard histogram 
does not do justice to the pixels resulting in the displayed intensity. To better represent 
the distribution of fluorescence intensity, the histograms are made in MATLAB and the 
axes readjusted to better represent the data. The frequency count axis is scaled by a base 
10 logarithm to better account for the lower number of pixels in the higher intensity 
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values. The range of intensity values plotted is also reduced to give a better view of the 





Figure 28. Histograms representing the pixel intensity distributions of the three images, 
corresponding to the a) 0 µg/mL, b) 2 µg/mL, and c) 20 µg/mL samples. The pattern of 
widened distributions does not hold through the HUVEC samples.  
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Fluorescence intensity distribution of the HUVECs reveals about the same 
amount of information as with the HBMECs. The narrow band present in the 0 µg/mL 
sample shows the reason for the lack of significant visualized fluorescence, much like in 
the HBMEC sample. Most of the contribution to the fluorescence comes from 
approximately 5 pixel intensities low in the spectrum. Considering how the background 
value has a pixel intensity of 3, there is not much of a jump between background and 
significant portions of the signal. This along with the lack of a 0-intensity pixel results in 
an image where most of the pixels are indistinguishable from the background noise. If a 
pixel value of 10 is arbitrarily taken to be visible, then less than 50 pixels are very visible, 
resulting in the few visible fluorescence areas.   
With the addition of TNF-α, the intensity distribution widens much like with 
HBMECs. However, the trend is not the same, as the 2µg/mL sample has a much wider 
distribution than the 20 µg/mL sample. The 2µg/mL sample has many values that are 
well above the arbitrary threshold of visibility. The wide distribution accounts for the 
increased VCAM-1 visibility as more fluorescence is distinguishable from background. 
The reasoning is slightly different for the final sample. The presence of a 0-intensity pixel 
allows for the background to be distinguishable from signal. The distribution is also 
slightly wider than in the 0 µg/mL sample; while there are fewer pixels above the 
arbitrary visibility limit than in the 20 µg/mL sample, it still allows for easier 
visualization of the VCAM-1. Also, with the background shifted because of the presence 








            Once again we can observe the expression trend in HUVECs in Figure 29. Much 
like in the HBMEC samples, the expression trend is logarithmic, as there is a large 
difference in fluorescence between the 0 µg/mL and 2 µg/mL samples, but not the 20 
µg/mL sample. As seen earlier, the difference between the 2 µg/mL and 20 µg/mL groups 
is almost zero. However, this is inline with what we have seen in the HBMECs, with the 
only difference being a lower magnitude of fluorescence. While the HUVECs are not 
present in the BBB, we have shown that the VCAM-1 expression trends are similar to the 
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Figure 29. Trends of VCAM-1 expression in HUVECs in relation to TNF-α. 
The expression trend once again looks logarithmic, although the difference in 
fluorescence between the 2 µg/mL and the 20 µg/mL samples is smaller than 
in the HBMECs. All points represent averages of two data points.  
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3.3.3 HUVEC Bead Experiments 
            HUVECs incubated with TNF-α and fluorescent beads are subjected to the same 
analysis as the VCAM-1 experiments. However, without any nucleus stain, MFIs are 
presented without the corresponding MPC value. Also, fluorescence is superimposed on 
phase contrast images as opposed to nucleus stains to show localization of bead uptake in 
relation to cells.  
    
a) b)  
 
Figure 30. Composite images and histograms depicting analysis of bead absorption in 
HUVECs incubated with no TNF-α. The a) 1 hour and b) 5 hour time points are shown, 
with a large increase in fluorescence visible. The white arrows indicate fluorescent bead 
aggregation around cells.  
 
             A comparison of the 1 and 5 hour time points is a rough way of estimating the 
baseline absorption kinetics of the HUVECs. For each 1-hour time point sample, 3 
images are presented corresponding to the levels of TNF-α used. For the sample without 
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TNF-α, the MFI across the trials is 29.1. Fluorescence is clearly visible in the sample, 
showing that these samples do not share the same troubles as the VCAM-1 staining. 
While not fluorescing intensely, the beads are clearly distinguishable from the 
background. Beads appear to localize in and near cells, showing the degree of non-
specific absorption in HUVECs. Another important observation is the degradation of the 
monolayer in the presence of the beads. Even without the presence of TNF-α, the 
monolayer is no longer tight, although the cell morphology is not changed significantly.  
    
a) b)  
 
Figure 31. Composite images and histograms depicting analysis of bead absorption in 
HUVECs incubated with 2 µg/mL TNF-α. The a) 1 hour and b) 5 hour time points are 
shown, with only marginal increases from the previous sample. The white arrows indicate 
fluorescent bead aggregation around cells. 
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a) b)  
 
Figure 32. Composite images and histograms depicting analysis of bead absorption in 
HUVECs incubated with 20 µg/mL TNF-α. The a) 1 hour and b) 5 hour time points are 
shown. Overall the trend from the VCAM-1 experiments are not necessarily maintained. 
The white arrows indicate fluorescent bead aggregation around cells. 
 
             The pattern of fluorescence for the two TNF-α samples looks similar to the 
results found in the VCAM-1 staining samples. Over the three samples of HUVECs 
incubated in 2 µg/mL TNF-α, the MFI is 28.1, whereas the MFI is 25.2 in the 20µg/mL 
sample. There is an evident dip in the number of beads absorbed by the cells in the final 
sample, something seen in the unadjusted HBMEC sample. The difference is that there is 
no adjustment in these results as the background is very much the same, thus the trend 
stands as is. Something to note in these samples is that cell layer morphology is changing 
in the presence of TNF-α, something not as evident in the VCAM-1 staining samples. 
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The monolayer is disrupted in both samples, with the 20 µg/mL sample suffering more. 
Despite the expectation that absorption should increase, TNF-α’s effect on the monolayer 
must also be taken into account.  
          For the five hour time points, bead localization increases as seen from a visual 
inspection. A higher concentration of beads also localize in and near cells at all three 
levels of TNF-α as seen by the increased levels of fluorescence at bead clusters. The 
pattern at 5 hours is mostly maintained; there are many clusters of fluorescence 
corresponding to more intact cells and a better cell layer for the sample without TNF-α. 
The MFI over 2 samples is 73.9, yielding approximately a 2.5x increase in fluorescence 
over the 4 hours. The MFI for the 2 µg/mL and 20 µg/mL sample is 62.1 and 59.3 
respectively over 2 and 3 images. These results correspond to a 2.2x and a 2.35x increase 
in fluorescence. Cell layer morphology patterns are seen once again as expected, which 
partially accounts for the trend seen in fluorescence levels.  
Distributions for all six sets of data do not yield much more information. Unlike 
the previous experiment, where the distributions changed significantly depending on the 
level of TNF-α, the shapes of the distributions are more or less the same at the one hour 
time points. The shape does not grow wider nor does the mean shift like in the VCAM-1 
experiments. At the five hour time points, the distribution towards the lower end of pixel 
intensities grow slightly wider with the addition of TNF-α, although this fact is not 
reflected by the mean intensity values. Despite the fluctuations in the fluorescence level, 
the results draw a rough picture of non-specific absorption by HUVECs which will be 









    
          For the bead absorption experiments, we see a slightly different trend, as seen in 
Figure 33. The absorption trend looks similar to exponential decay, indicating a 
logarithmic decrease in fluorescence in relation to TNF-α. The maximum amount of 
fluorescence occurs in the bead sample incubated without TNF-α and the minimum 
occurs in the sample incubated with 20 µg/mL TNF-α. The trend is more noticeable at the 
5-hour time point as the magnitude of fluorescence is higher. As we can see, the trends 
are inversely correlated with VCAM-1 expression; less bead absorption occurs with 
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Figure 33. Trends of non-specific bead absorption in HUVECs. The 1-hour 
and 5-hour time points are shown. At both time points, both trends appear to be 
similar to exponential decay as opposed to the logarithmic trend in VCAM-1 
expression. All points represent averages of two data points, with the exception 
of the 5-hour 20 µg/mL group, which averages three.  
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3.4 Blood Brain Barrier Discussion 
Before discussing the results presented in the section above, we would like to first 
address the simplicities that we made in our BBB model formation, as we recognize that 
this likely plays a significant role in results obtained.  As described in the background of 
this section, the in vivo BBB is not only composed of ECs with TJs, but also includes 
basal lamina, pericytes, astrocytes, interneurons, and microglia58.   
The first steps in developing this complex BBB model were to culture ECs on the 
Transwell surface without any other components, and to then measure the corresponding 
electrical resistance values to establish barrier characteristics.  It was at this point that we 
ran into several problems, including the inability to produce consistent electrical 
resistance values, and the presence of excessive debris in the inserts.  As we ran into 
these problems, we came to realize that we did not have a budget to support the continued 
purchase of these Transwell inserts nor the purchase of materials needed to start up and 
maintain the other cell lines that we would eventually want to add to the model.  Because 
of these monetary and time constraints, many simplifications needed to be made to our 
BBB model.  The Transwell inserts and additional cell lines were removed from our list 
of materials, as were components for use in synthesizing hydrogels.  What we were left 
with, then, was a glass coverslip to which we would grow our EC monolayer.  We realize 
that this final BBB model use in our experiments has many limitations.  For example, 
without a hydrogel, or some sort of permeable substance/membrane, we cannot evaluate 
the effectiveness of our drug delivery model’s movement within the ‘brain’ portion of the 
BBB model.  Instead, we focus on strictly understanding the ability of our drug delivery 
complex to utilize VCAM-1 proteins expressed on the apical surface of the endothelium 
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as a method of beginning the traversing process.  For the short term, showing that 
VCAM-1 can be used as a targeting molecule to help deliver drugs through the BBB 
would provide a solid foundation for future studies that, when using a more complex and 
developed in vitro BBB model, could explore how these drug delivery mechanisms 
interact with the rest of the BBB and brain once they pass the endothelial layer. 
          There are two key aspects to this portion of the overall experimental plan: 
characterizing VCAM-1 expression under the influence of TNF-α, and obtaining a rough 
estimate of the non-specific absorption properties of HUVECs.   
 
3.4.1 Characterizing VCAM-1 Expression under the Influence of TNF-α 
Ideally, HBMECs would have been the cell type used in the in vitro BBB model. 
However, a variety of problems stifled the ability for the cells to produce viable and 
reproducible results. After the VCAM-1 staining, the HBMECs were unable to grow in a 
healthy and predictable manner (others report difficulties in HBMEC culture as well), 
forcing a change to HUVECs.80  We recognize that there are significant differences 
between these two cell lines, as HBMECs are used more in micro-circulatory studies and 
HUVECs are used in more macro-circulatory studies81.  For example, while perhaps not a 
very significant difference for the purposes of our studies, HBMECs and HUVECs 
respond very differently to certain xenobiotics.82 Another example is the difference in 
glycosphingolipid (GSL) patterns between HBMECs and HUVECs; in particular, the 
amount of globotriaosylceramide (Gb3), a neutral GSL, in HBMECs is approximately 
double that found in HUVECs.80  While this may not seem to be of much importance 
here, as we are not interested in the effects of GSL expression for our drug delivery 
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method, it is interesting to note that other studies have found that Gb3 induces oxidative 
stress as well as up-regulates the expression of ICAM-1, E-selectin, and VCAM-1 in ECs 
related to Fabry disease.83  Clearly, there are differences between HBMECs and 
HUVECs that would give preference to the use of HBMECs in our model since they 
would help us more closely replicate the in vivo conditions of the BBB.  However, given 
that both cell types are human ECs, we expected that, despite their differences, their 
similarities in simple behavior and adhesion protein expression would allow for HUVECs 
to be a reasonable analog for our purposes.  
With VCAM-1 as the nanoparticle’s target, it was imperative that we characterize 
the difference in this protein expression between the two cell types. Without a handle on 
the difference, we cannot justify the use of HUVECs in our model. One problem that 
arose in the HBMECs was the VCAM-1 response to TNF-α. With increased levels of 
cytokines, VCAM-1 expression is expected to increase.84,85 However, with the highest 
concentration of TNF-α (20 µg/mL), VCAM-1 expression actually decreases throughout 
the sample. An interesting observation from the experiments is the lack of expression in 
certain areas of the 20 µg/mL sample, which accounts for the lower fluorescence values. 
The only noticeable patterns as the concentration of TNF-α increased were fewer cells 
expressing VCAM-1 and the distribution of VCAM-1 expression within cells becoming 
increasingly patchy. 
           As mentioned earlier, there is a large disparity in fluorescence between the 2 
µg/mL and 20 µg/mL samples. While the two samples look similar visually, the 
underlying fluorescence intensity differs. If VCAM-1 expression increased as expected, 
more fluorescence would be seen along with it. Instead, both the total fluorescence and 
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the normalized fluorescence intensities at the highest concentration of TNF-α are similar 
to the control, the sample that was not incubated with any TNF-α. The caveat is the 
distribution of pixel values. Normally this would not be an issue; however in this case, 
there may be one. The background signal for the control case is much higher than the 
highest concentration case, although it is similar to the middle case. With such high 
intensity background noise, weak signals are indistinguishable, as seen in the control 
case. A result of the increased background noise is a higher mean fluorescence, as the 
background essentially shifts all the pixel intensities by a certain constant. The middle 
case is visible because the distribution extends beyond the background even though the 
baseline value for the highest level is actually much lower than the other two, which 
contributes to the lack of a trend. Once the background is eliminated, a clearer positive 
trend appears - which was expected. The large difference in level of expression between 
the control and middle data points is preserved, as the background level is approximately 
the same for the two. With the background eliminated, it is clear that there is more 
fluorescence – more VCAM-1 expression – with higher levels of TNF-α. It is possible to 
eliminate the background because it acts as the baseline for the image. As seen in the first 
image, almost none of the VCAM-1 expression is clearly seen in the fluorescence despite 
intensities on par with the other groups. However, most of the image is just background 
noise which doesn’t contribute to the fluorescence. Since it is not a result of the actual 
fluorescence, it is skewing the data. Readjusting the data does not affect the information 
present; it simply brings it to light. Therefore, results show a positive logarithmic trend: 
increasing amounts of TNF-α cause increasing expression of the VCAM-1 protein in the 
HBMEC monolayer.  
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VCAM-1 expression data in HUVECs suffers from the same problems as the 
unadjusted HBMEC data. In the HUVEC images, however, the data cannot be adjusted to 
show the same type of information. Unlike the HBMECs, the HUVECs in general have 
much lower expression of VCAM-1, as seen in the results section. Because of this, all 
three samples show low fluorescence totals, and this time, the background values are 
approximately the same. Thus, there is no adjustment to the histograms, and the MFIs for 
the two TNF-α samples are more or less the same.  This suggests that TNF-α only 
regulates VCAM-1 expression up to a certain threshold, perhaps below or around a 
concentration of 2 µg/mL, in HUVECs. The only indication that VCAM-1 expression 
might go up is when the fluorescence values are normalized to the number of cells, in 
which case there is a slight increase on par with the increase seen in the HBMEC 
samples. The minor increase is reasonable, given how little fluorescence is present.  
However, an issue arises with the normalization, as across all the normalized 
values, there is almost no difference between the control and the middle (2 µg/mL) 
sample. Despite the clear visual difference between the two samples, the normalization 
results suggest that the two are no different. Upon speculation, normalization is most 
likely not the most reasonable option. For example, the middle sample clearly has more 
cells than either of the other samples, but when compared to the higher sample, 
fluorescence is approximately the same. Given the density of cells in the sample, there is 
less area per cell for VCAM-1 expression. Although the same amount may be expressed 
across all the cells, each cell produces less, yielding a lower normalized value. Even 
though we can use the normalized value to gain an understanding of what is happening 
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on a per-cell basis, it is more likely that the mean total fluorescence is more objective for 
use in drawing any substantial conclusions.  
Despite the fact that the fluorescence levels differ very little between the two 
experimental groups, there is a definite up-regulation in the presence of TNF-α. This 
result bodes well for the purposes of our BBB model, as it shows that HBMECs and 
HUVECs react similarly in the presence of TNF-α in regards to VCAM-1 expression. 
Granted, level of expression is on a different order, which will affect how effective 
targeting the protein is, but the overall action should remain the same. We suspect that 
there exist other morphological changes that differ between the two cell types under 
cytokine stimulation, which could be confounding variables when using the HUVECs 
and our simplistic BBB model.  However, the most important aspect for the purposes of 
our experimentation is VCAM-1. Without the similarity present, it would be unfeasible to 
expect the HUVECs to act as a good model for targeting.  
 
3.4.2 Characterizing Non-specific and VCAM-1 related Absorption in HUVECs 
Justifying the use of HUVECs in our model was only the first step, however. The 
next step was to form an understanding of non-specific absorption. We must be able to 
compare baseline absorption of the HUVEC monolayer under normal conditions to the 
specific absorption caused by the VCAM-1 targeting. Fluorescent beads are not 
specifically absorbed by cells and will act as a control to the nanoparticle testing. Due to 
previously mentioned problems with HBMEC culture, only HUVEC absorption is 
characterized. Since bead uptake is not specific, it was expected that HUVEC monolayers 
would absorb more fluorescent beads over time.  Additionally, it was hypothesized that 
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on top of the already-present non-specific absorption, increasing VCAM-1 expression 
through the TNF-α pathway would result in even greater bead uptake. 
While absorption is clear over the five hours observed, the levels of absorption are 
not as expected. At both the one and five hour time points, it appears that the introduction 
of either 2 or 20 µg/mL of TNF-α increases absorption marginally compared to the 
control sample, but increasing the concentration from 2 to 20 µg/mL only serves to 
decrease overall absorption when making comparisons solely between the two. This does 
not necessarily match any of the trends seen in the VCAM-1 experiments, which is 
disconcerting. The only time this shows up is in the unadjusted HBMEC data. Once 
again, the data is not as easily adjusted in this case, as the background across all the 
samples nearly identical. Any adjustments would yield negligible changes and the overall 
trend remains. We suggest the existence of a saturation level with TNF-α that may result 
in excessive concentrations giving conflicting results.   
One of the more important results is the effect that TNF-α has on the cell 
monolayer. Although the absorption trend is not easily gleaned, the cell layer clearly 
changes in all the samples. Disruption is easy to see, as gaps between cells are more 
frequent and morphology is shifting away from those seen in a normal, healthy 
monolayer. This could partially explain why the trend observed and explained above is 
inconsistent with the VCAM-1 experiments. With the HUVECs, the pattern of VCAM-1 
expression showed that even with the TNF-α, the monolayer was still relatively intact. 
The combination of the beads and TNF-α caused deterioration that is inconsistent with 
monolayer morphology observed with only TNF-α. This, in turn, caused an unexpected 
change in results. It is likely that the introduction of the beads was enough of a stimulus 
 79 
to enable the deterioration, as even without TNF-α, there is a degree of disruption in the 
monolayer.  With the amount of molecules in the vascular circulation at any given time, 
we believe that the introduction of beads should not have been enough to cause 
monolayer disruption.  This leads us to suspect our simplistic BBB model as one of the 
contributing factors to this problem.  We believe that future studies that use a more robust 
BBB model, with hydrogel, astrocytes, and other glial cells, would provide for the 
additional structural stability innate to the BBB endothelium.  Another consideration is 
that our model lacks flow, something with is clearly present in vivo in circulation.  
Perhaps it was the static presence of the beads that contributed to the monolayer’s 
disruption.  Regardless, we recognize that our model likely played a role in some of the 
problems we saw in our experiments. 
Because of this monolayer disruption, it is better to normalize the fluorescence 
intensities to the number of cells, as the space issue is less of a factor when the monolayer 
is disrupted. However, nucleus staining was not taken during the bead experiments, 
making cell counting more difficult. There are clearly cells in the sample, however, there 
are also other structures that look like cells that are much harder to discern under only 
phase microscopy. Attempting to count the number of cells would likely result in 
inconsistent results which would not aid our experiments. It is safer to use the non-
normalized data; however the point is made that repeating experiments and normalizing 
the data could results in more consistent results. 
Understanding the baseline absorption is somewhat difficult with only two time 
points available. Given that kinetics are driven by concentrations, we can assume that 
absorption follows a decaying exponential; however with only two points, it is still 
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difficult to characterize the curve – but it is still possible to obtain some useful 
information. We can still compare the fluorescence levels with other experiments to see 
the relative absorption rates. For example, the ratio of bead absorption at a particular time 
point is approximately two times as high as the previous time point. If we see that a 
different experiment exhibits significantly differing ratios and values, the mechanics of 
absorption are probably not using non-specific pathways.  
          To summarize, experiments aiming to obtain a rough estimate of the non-specific 
absorption properties of HUVECs suggest that most bead uptake was indeed non-
specific, with increased VCAM-1 expression only marginally increasing absorption.  
While not agreeing with initial hypotheses, a TNF-α concentration of 2 µg/mL and bead 




          The results from the BBB model section of our overall research plan highlight 
some important results that are important as we move forward.  First, VCAM-1 
expression, in general, increases as the concentration of TNF-α increases in HBMECs 
and HUVECs.  In HUVECs, smaller concentrations of TNF-α and increasing time result 
in larger bead absorption, indicating that in at least some capacity, VCAM-1-specific 
interactions help in molecule absorption. Overall, our results support our decision to use 
VCAM-1 as a targeting molecule for our nanoparticle-based drug delivery system. 
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4. Nanoparticle Complex 
4.1 Nanoparticle Complex Background 
4.1.1 Cationic Solid Lipid Nanoparticles 
Nanoparticles have been considered in previous studies as possible carriers for 
drugs across the BBB.30,31,33 However, nanoparticles are broadly defined as solid 
colloidal particles ranging from 1-1000 nm in diameter, and there are several different 
types of nanoparticles which researchers have investigated.30,31,86,87 Inorganic options for 
nanoparticles were not chosen for this study due to adverse effects caused by the lack of 
biodegradation of these materials, such as gold or silica, in vivo.31 Nanoparticles formed 
traditionally by emulsion polymerization were also ruled out due the requirement that 
free radicals, radiation, or UV light are generally needed to trigger polymerization, as 
well as the dialysis necessary to purify these nanoparticles and maintain stability.86 We 
further ruled out nanoparticle types which would have required our drug substitute 
(BODIPY-TMR) be attached to the surface of the particle to eliminate the possibility of 
the dye interacting with entities outside of the nanoparticles.  
          SLNs have been shown to have a high drug load capacity, a low incidence of 
toxicity in the body, and high stability during long term storage.30 Studies have also 
shown that SLNs can be used for the sustained release of therapeutic agents, which 
demonstrates stability in vivo.88 In addition to showing promise in the delivery of drugs 
throughout the body, there has also been success in targeting SLNs to the brain.30,89,90,91 
          The CSLNs used in this study were created based on a protocol developed by Kim 
et al.29 While Kim utilized the carrying capacity of CSLNs to deliver siRNA to body 
cells, we will be exploiting the structure of CSLNs to carry a fluorescent dye, which will 
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simulate a drug, through the BBB. The CSLN components were based on the structure of 
low density lipoprotein (LDL) cholesterol complexes. LDL cholesterol is a naturally 
occurring nanoparticle abundant in the body, limiting the possibility of toxicity caused by 
the drug complex. Natural LDL nanoparticles have also been used previously in delivery 
of DNA for therapeutic purposes.29 Creating CSLNs from the components of LDL rather 
than using naturally occurring LDL allows dye to be incorporated during the formation of 
the nanoparticles. Creating CSLNs is also more economically feasible than isolating 
naturally occurring LDL.  
 
Figure 34. This image shows the composition of LDL. LDL is made up of many 
components, and so would be difficult to isolate naturally. 
Cardiologydoc, cardiologydoc.wordpress.com 
 
The nanoparticles used in this study are composed of cholesteryl oleate, glyceryl 
trioleate, DOPE, cholesterol, and DC-cholesterol. DOPE and cholesterol are incorporated 
in the nanoparticles because they are known to improve and stability and reduce the 
cytotoxicity of cationic lipids.29 In particular, DOPE also facilitates the fusion of CSLNs 
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with endosomal membrane phospholipids.29 Cholesterol was incorporated to provide 
morphological rigidity to the surface and to promote the stability of CSLNs.29 DC-
cholesterol was introduced as the major cationic lipid to generate positively charged 
CSLNs, since DC-cholesterol is considered to be less toxic than other comparable 
cationic lipids.29 DC-cholesterol based carriers were approved in many clinical 
treatments, such as melanoma, cystic fibrosis, and breast cancers.29 Based on previous 
literature, the ratio of DOPE to cholesterol to DC cholesterol in this protocol is at near 
optimal molar ratio for efficient liposome formulations.29 The core of natural LDL is 
composed of cholesteryl ester and triglyceride.29 
 









Streptavidin is a crystalline protein purified from the bacterium Streptomyces 
avidinii.92 It is a 60 kDa tetrameric protein with four subunits, and has an extremely high 
affinity for biotin, which will be explained in greater detail later.92 The quaternary 
structure of the streptavidin protein is composed of four streptavidin monomers, each 
composed of eight antiparallel β-turns that fold to form a β-barrel tertiary structure.93 
Each subunit contains a biotin binding site, giving each molecule of streptavidin a total of 
four biotin binding sites.93  
 
Figure 36. Attaching streptavidin to nanoparticles is the first step of the drug delivery 
complex; the streptavidin binds to nanoparticles due to electrostatic interactions. Figure 
not drawn according to scale. 
 
At pH 7.2, streptavidin has a net negative charge because it has an acidic 
isoelectric point (pI = 5).92 Streptavidin’s negative charge allows it to bind with the 
positively charged SLNs in neutral biological conditions through electrostatic 
interactions. It is expected that in solution, streptavidin and SLNs will naturally aggregate 
and stick together, which completes the first part of our nanoparticle complex. The 
 85 
purpose of streptavidin in this experiment is to act as a “glue” to connect the nanoparticle 
to the biotin. Since streptavidin is electrochemically attracted to the nanoparticle, and the 
biotin-streptavidin bond is the strongest non-covalent bond found in nature, streptavidin 
is the optimal linker between the nanoparticle and biotin.94,95,96 
 
4.1.3 Biotin 
The next component of the complex is biotin. Biotin is a vitamin (also known as 
Vitamin H or Vitamin B7) that is present in all living cells and is essential for numerous 
biological processes including cell growth, the production of fatty acids, and the 
functioning of the citric acid cycle. Biotin also works in the body to help transfer carbon 
dioxide, maintain a steady blood sugar level, and strengthen hair and nails. While biotin 
has many important functions as a chemical regulator in the body, biotin also plays an 
important role in biotechnology.94 Because biotin is only 244.3 daltons, it is a relatively 
small molecule that can be conjugated to other proteins and molecules without 
significantly altering their biological activity.94 Specifically, the streptavidin protein 
binds biotin with high affinity (Kd = 10-14 mol/L) and specificity94,95,96. The streptavidin-
biotin complex is the strongest known non-covalent interaction between a protein and a 
ligand.94,95,96  
The remarkable affinity of streptavidin to biotin has been closely inspected using 
crystal structures.95 First, the biotin-binding site on streptavidin highly complements the 
biotin shape, making for an easy fit for biotin.95,96 In addition, there is an extensive 
network of hydrogen bonds formed between streptavidin and biotin once biotin is in the 
binding site.95,96 Hydrogen bonds are the strongest type of non-covalent bonds found in 
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nature, and add to the stability of the streptavidin-biotin complex. However, the 
streptavidin-biotin affinity is stronger than what would be expected from the hydrogen 
bond interactions alone, which indicates that there are other mechanisms in place to 
stabilize the bond even further.95,96 One such mechanism is that the biotin binding site is 
hydrophobic, and there are several hydrophobic interactions made to the biotin in the 
binding site that contribute to the affinity.95,96 Finally, biotin binding is accompanied by a 
flexible loop that extends over the bound biotin, acting as a cover over the binding site 
and accounts for the very high affinity between streptavidin and biotin.95,96 
 
Figure 37. This diagram demonstrates that streptavidin has four biotin-binding sites. This 
means that each streptavidin protein can bind up to four biotin molecules. Figure is not 
drawn to scale. 
 
The formation of the bond between streptavidin and biotin occurs very quickly, 
and once it forms, it is unaffected by extremes of temperature, pH, organic solvents, and 
other denaturing agents.96 These features of the streptavidin-biotin bond are often 




4.1.4 Complete Complex 
In the context of this experiment, biotin is used to connect an antibody to 
streptavidin, which is attached to a nanoparticle. We used a biotinylated VCAM-1 
antibody (biotin conjugated to the antibody) to attach to streptavidin to complete the final 
nanoparticle complex. The VCAM-1 antibody is used for specific targeting of the 
VCAM-1 proteins on the BBB monolayer, so that the nanoparticle is delivered in a 
specific manner. Each streptavidin protein has the ability to bind up to four biotin 
molecules, as shown in the diagram below.  
In this experiment, biotin has a similar role as streptavidin does, in that biotin 
functions as a “glue” to connect the nanoparticle to the antibody. The biotin of the 
prepared biotinylated VCAM-1 antibody naturally attaches to streptavidin in solution, 
due to the extremely high streptavidin-biotin attraction in nature. Meanwhile, streptavidin 
is also attached to a CSLN, due to the electrochemical attraction between the positively 
charged nanoparticle and the negatively charged streptavidin. Ideally, the complete 
nanoparticle complex is composed of a nanoparticle conjugated to a streptavidin protein, 
which is subsequently attached to four biotinylated VCAM-1 antibodies, as diagrammed 




Figure 38. This diagram shows the completed drug delivery complex, which includes a 
cationic solid lipid nanoparticle (yellow), attached to streptavidin (blue), which is then 
subsequently attached to a biotinylated VCAM-1 antibody (orange, red). As evidence in 
the diagram, since each streptavidin has four biotin-binding sites, streptavidin can bind 
four biotinylated antibodies. Figure is not drawn to scale. 
 
4.1.5 Fluorescent Dye 
The dye used to visualize the nanoparticles is BODIPY® TMR maleimide.  The 
BODIPY TMR dye is hydrophobic, which allows it to be incorporated into the 
hydrophobic core of CSLNs.97  It is also lacks ionic charge, preventing it from interfering 
with the other charged components of the nanoparticle complex.97 These two properties 
make BODIPY TMR an ideal dye for visualization of the nanoparticle complex. 
BODIPY TMR is also used to imitate how a real pharmacological drug would act in our 
drug delivery model. Since choosing and utilizing a real drug lies beyond the scope of our 
current project, using BODIPY TMR serves the dual purposes of visualization of the 
nanoparticle complex and simulation of a real drug. 
                BODIPY TMR peaks in fluorescence emission when it absorbs light at 
570nm.97 The dye has a green fluorescence similar to that of Fluorescein Isothiocyanate 
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(FITC).97 Thus, BODIPY TMR is compatible with standard optical filter sets designed 
for FITC, which is standard on most microscopes that have fluorescent filters.  
	  
Figure 39. This figure shows the emission spectrum of BODIPY TMR. As shown in the 
graph, BODIPY TMR peaks in flourescence at around 570 nm. 
 
This dye is not visually shown in the diagram of the nanoparticle complex 
because it will be encapsulated inside the hollow space of the nanoparticle. 
 
4.2 Nanoparticle Complex Methodology 
The nanoparticle complex with streptavidin was created in a series of two steps. 
The two steps were to create the nanoparticle and then attaching the streptavidin to the 





4.2.1 Creating the Nanoparticle 
The following compounds listed below were added into a vial of 
chloroform:methanol mixture (2mL, 2:1 ration per volume).  
 
cholesteryl oleate 22.5mg, 45% w/w 
glyceryl trioleate 1.5mg, 3% w/w 
DOPE 7mg, 14% w/w 
cholesterol 5mg, 10% w/w 
DC-cholesterol 14mg, 28% w/w 
BODIPY TMR dye fluoresces at 561nm, 8uL 
 
Afterwards, 10mL of deionized water was added to the mixture and then vortexed 
thoroughly.29 The suspension was sonicated thoroughly for 16 minutes at 60Hz.29 The 
micro emulsion solution left over after the sonicating was then transferred to a reduced 
pressure solvent removal apparatus and removed above 52 Celsius. The melting point of 
cholesteryl oleate is 52 Celsius. The prepared SLN emulsion was stored at 4o Celsius.29 
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Figure 40. Typical phospholipid bilayer membrane with transmembrane proteins  
AP Biology, http://www.biologycorner.com/APbiology 
 
4.2.2 Adding Streptavidin 
To create the complex with streptavidin, .5mg of streptavidin was added to 3mL 
of nanoparticle suspension in a vial.29 The mixture of streptavidin and nanoparticle 
suspension was then sonicated for 8 minutes. The mixture of streptavidin and 
nanoparticle suspension was then placed into a 4 Celsius fridge for storage.29 
 
4.2.3 Adding Biotinylated Antibody 
To create the complex with biotinylated anti-VCAM-1, 30ug of biotinylated anti-
VCAM-1 (purchased from eBioscience) and 10 mL of nanoparticle-streptavidin 
suspension was added in a vial. The mixture of biotinylated antibody and nanoparticle-
streptavidin suspension was then sonicated for 11 minutes. The mixture of biotinylated 




4.2.4 Confirmation of the Nanoparticle Complex 
In order to confirm whether the nanoparticle and streptavidin has been attached, a 
series of four experiments were conducted in the following order below:  
1. Nanoparticles and streptavidin on glass microscope slides were coated in a layer 
of biotin plates that were purchased from Xenopore.  
2. Nanoparticles and streptavidin on non-biotin plate.  
3. Nanoparticles on biotin plates. 
4. Nanoparticles on non-biotin plates.  
For each of the experiments listed above, 85uL of nanoparticle suspension was placed on 
a plate.29 After waiting 2 minutes, the suspension on the plate was washed under de-
ionized water and dried with Kim wipes in order to view the complex under 20x 
objective microscope with fluorescent filter 561nm.  
All of the images collected from the experiments listed above were analyzed with 
ImageJ. 
 
4.3 Nanoparticle Complex Data and Results 
4.3.1 Maximize NP Size Uniformity and Reduce Contamination via Filtering  
4.3.1.1 Unfiltered Nanoparticles 
          As shown in Figure 41 below, the nanoparticles initially formed were of non-
uniform size and shape. Using ImageJ for analysis, an average particle size was 
determined for each individual picture, as well as the standard deviation for the 
distribution of particle size within each picture. In order to increase the likelihood that the 
program was recognizing individual nanoparticles rather than conglomerations of 
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particles or other contaminates that may have been on the slide, only particles with a 
circularity (defined by 4π(A/C2), where A equals area of the circle and C equals 
circumference of the circle. A value of 1.00 denotes a perfect circle) of 0.99–1.00. 
          Due to the limitations of ImageJ, 
along with issues with the equipment 
used to obtain the pictures, it cannot be 
assumed that the average particle size is 
only taking into account the sizes of 
nanoparticles themselves. The ImageJ 
analysis has been used as a comparison 
between the filtered and unfiltered 
nanoparticles, not as a definitive 
measure of nanoparticle size.  
           The particles in Figure 41.1 were 
found to have an average particle size of 
381.4 nm, after the removal of extreme 
outliers from the data (Extreme outliers 
defined as particles more than 3 standard 
deviations from the mean as calculated 
by ImageJ). The distribution of particle 
size can be seen in Figure 43.1. The 
particles in Figure 31.1 have a fairly 
wide distribution. The particle sizes 
 
 
Figure 41 shows three separate photos of 
the nanoparticles before filtering. These 
same photos were later used for 





range from 100.6 nm to 5027.6 nm, with continuous peaks between 100.6 nanometers 
and 1907.1 nanometers.  
The particles in Figure 41.2 were found to have an average particle size of 282.4 
nm, after the removal of extreme outliers from the data. The distribution of particle size 
can be seen in Figure 43.2. The particles in Figure 41.2 have a fairly wide distribution. 
The particle sizes range from 100.6 nm to 4625.4 nm, with continuous peaks between 
100.6 nanometers and 2061.3 nanometers. 
The particles in Figure 41.3 were found to 
have an average particle size of 203.2 nm, 
after the removal of extreme outliers from 
the data. This lower average as compared 
to the other filtered samples may be 
attributed to issues with the image quality 
in the format needed for ImageJ analysis. 
The distribution of particle size can be 
seen in Figure 43.3. The particles in 
Figure 41.3 have a slightly smaller 
distribution than the other unfiltered 
nanoparticle samples. The particle sizes 
range from 100.6 nm to 2815.5 nm, with 
continuous peaks between 100.6 
nanometers and 1729.5 nanometers. 
Figure 42 shows three separate photos of 
the nanoparticles after filtering. These same 
photos were later used for comparison to 






4.3.1.2 Filtered Nanoparticles 
The particles in Figure 42 were passed through a 200 nm filter in order to produce 
particles of a more uniform size and of a more optimal size with which to cross the BBB.  
           The particles in Figure 43.4 were found to have an average particle size of 305.3 
nm, after the removal of extreme outliers from the data. The distribution of particle size 
can be seen in Figure 43.4. The particles in Figure 42.4 have a more narrow distribution 
that the majority of the unfiltered nanoparticles. The particle sizes range from 100.6 nm 
to 3720.4 nm, with continuous peaks between 100.6 nanometers and 1789.8 nanometers. 
These peaks are much shorter on average than those from the distribution the unfiltered 
particles. 
           The particles in Figure 42.5 were found to have an average particle size of 211.7 
nm, after the removal of extreme outliers from the data. The distribution of particle size 
can be seen in Figure 43.5. The particles in Figure 42.5 have a more narrow distribution 
that the majority of the unfiltered nanoparticles. The particle sizes range from 100.6 nm 
to 1508.3 nm, with peaks between 100.6 nanometers and 663.6 nanometers, though they 
are not continuous.  
           The particles in Figure 42.6 were found to have an average particle size of 257.5 
nm, after the removal of extreme outliers from the data. The distribution of particle size 
can be seen in Figure 43.6. The particles in Figure 42.6 have a more narrow distribution 
that the majority of the unfiltered nanoparticles. The particle sizes range from 100.6 nm 
to 4122.6 nm, with continuous peaks between 100.6 nanometers and 1141.3 nanometers. 
These peaks are much shorter on average than those from the distribution the unfiltered 



















4.3.2 Test that the Nanoparticle can Attach to Streptavidin 
The purpose of this experiment was to demonstrate that the CSLNs were able to 
successfully bind to streptavidin.  Samples of nanoparticles and nanoparticle-streptavidin 
conjugates were placed on both normal microscope slides and biotin-coated slides.  The 
slides were then washed, leaving behind particles that were the most adherent to the 
Figure 43 shows the size distribution of the nanoparticles imaged in 
Figures 41 and 42. Figures 1-3 are of the unfiltered nanoparticles, and 
Figures 4-6 are of the filtered nanoparticles.  The x-axis is the size of 
nanoparticles in micrometers for all graphs; the y-axis is the number 









slides.  The slides were then observed under fluorescence microscopy to determine 
whether the samples successfully attached to the slides.   
Condition Average Number of Particles per Frame  
Trial 1 Trial 2 
NP on biotin-coated slide 1.1 1.3 
NP on normal slide 0.1 0.2 
NP-Strep on biotin-coated 
slide 
24.7 19.9 
NP-Strep on normal slide 4.3 0.2 
Table 4. Counting nanoparticles 
Ten pictures were taken for each trial, with each photograph illustrating a 
different field of view.  The average number of particles in each frame per condition was 







   
Figure 44.  NP on biotin-coated slide               Figure 45.  NP on normal slide 
   
Figure 46.  NP-strep on biotin-coated slide       Figure 47.  NP-strep on normal slide 
Figures 44-47 are photographs selected from each condition of the experiment.   
Each figure was selected to best represent the relative averages particles listed in Table 4.  
Figure 45 is a photograph of a nanoparticles on a biotin-coated slide, and there is 1 
particle in view.   Figure 45 is a photograph of nanoparticles on a normal slide, and there 
are no particles in view.   Figure 46 is a photograph of nanoparticle complexes on a 
biotin-coated slide, and there are 30 particles in view.  Figure 47 is a photograph of 
nanoparticle complexes on a normal slide, and there are 6 particles in view.    
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4.3.3 Test that Streptavidin can Attach to Biotin 
The following results are from an experiment to validate that streptavidin is able 
to attach to biotin. We hypothesized that fluorescence and the number of nanoparticles 
observed in each image will decrease the longer the incubation time. 
 






























The following chart reveals the number of fluorescent nanoparticles observed in each 
image, at each time point of incubation. 
Number of fluorescent nanoparticles observed in each image 
Time point 2 hour 4 hour  8 hour 
 3 4 4 
 7 2 1 
 4 5 3 
 6 3 1 
Average  5 2.8 1.8 
Table 5. Counting fluorescent nanoparticles. As evidenced by the decreased number of 
nanoparticles observed on average in each image as length of incubation increased, this 
experiment confirms that streptavidin is able to attach to biotin. 
 
4.3.4 Determining the Concentration of Nanoparticles in Solution 
            After pipetting 20 µL of nanoparticle solution onto a microscope slide, we laid a 
cover-slip on top of the droplet such that the droplet covered the entire face of the cover-
slip. We proceeded to take fourteen images of the nanoparticles in random places at 20x 
magnification using fluorescence microscopy. We used the following fourteen images (as 










We then counted the number of fluorescent particles that appeared in each image, took 
the average, and proceeded to calculate the concentration of the nanoparticle solution 
from there. 
















Table 6. This table displays the number of fluorescent particles counted in each of the 
fourteen images shown above, under fluorescent microscopy. 
 
           The average number of nanoparticles observed was 28.5 nanoparticles per image. 
Based on the magnification of 20x and the 0.3171 µm/pixel scale of the microscope, each 
image was determined to have the dimensions of 441.4 x 10-6 m by 329.78 x 10-6 m 
through ImageJ analysis. This means that each image had an area of 0.14556 x 10-6 m2, or 
0.14556 µm2. So rudimentarily, there are 28.5 nanoparticles per 0.14556 µm 2. Each 
coverslip has dimensions of 20 x 10-3 m by 20 x 10-3 m, which yields an area of 400 um2 
for each coverslip. Since each image had an area of 0.14556 µm 2, this means that 
dividing the area of each coverslip by the area of each image would yield the number of 
images that could fit onto one coverslip: 400 µm 2 / 0.14556 µm 2 = 2748.008 
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images/coverslip. To determine how many nanoparticles existed on one coverslip, we 
multiplied 28.5 nanoparticles/image by 2748.008 images/coverslip to yield 78,318.22 
nanoparticles/coverslip. Each coverslip contained 20 µL of nanoparticle solution, so 
78,318.22 nanoparticles / 20 µL solution = 3915.9 nanoparticles/ µL. The concentration 
of our nanoparticles is roughly 3900 nanoparticles per µL. We recognize that this method 
of determining our nanoparticle concentration is not precise, but this method does 
provide us with a rough estimation that is sufficient for the purposes of our project.  
 
4.4 Nanoparticle Complex Discussion 
4.4.1 Maximize NP Size Uniformity and Reduce Contamination via Filtering 
Once the nanoparticles had successfully formed, pictures were taken using the 
ImageJ software. The images were taken for several reasons: to further confirm the 
formation of the nanoparticles and to determine the size of the formed nanoparticles. Due 
to the limitations of ImageJ and “noise” present in the pictures used for analysis, the 





As shown in Table 7, the filtered nanoparticles have a lower average area than the 
unfiltered particles. These results show that overall, the size of the nanoparticles 
decreased after the unfiltered particles were passed through the 0.200 µm filter. A smaller 
particle size is favorable to permeating the BBB model because a smaller particle will 
more easily sift through the physical membrane. Thus, a smaller particle size increases 
the likelihood that the drug complex will be capable of passing through the BBB model.  
Table 7 shows the standard deviation of the average areas of the filtered and unfiltered 
nanoparticles. The unfiltered nanoparticles have an average size of 289 nm  +/- 89.3. The 
filtered nanoparticles have an average size of 241.8 nm +/- 56.1. The smaller standard 
deviation in the areas of the filtered particles  indicates that more of the particles are 
closer to the average size. From this it can be concluded that the nanoparticles are of a 
more uniform size once they have been passed through the filter.  




381.4  282.4  203.2  289  +/- 89.3  
Filtered 
Nanoparticles 
305.3  199  221.1  241.8  +/-56.1  
 
Table 7. Average nanoparticle area in each sample after the removal of extreme outliers from 
the data, as well as overall averages and standard deviations between the average particle sizes 
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Figure 48. S distribution of the nanoparticles before and after filtering. Figures 1-3 are of 
the unfiltered nanoparticles, and Figures 4-6 are of the filtered nanoparticles. The x-axis 
is the size of nanoparticles in micrometers for all graphs; the y-axis is the number of 
nanoparticles, for all graphs. 
 
 
Figure 48 shows the size distribution of the filtered and unfiltered nanoparticles. 
On average, the filtered nanoparticles have a higher percentage of particles which are of a 
smaller size. The unfiltered nanoparticles have more individual particles of higher sizes. 
These distributions further support the conclusion that filtering the nanoparticles result in 
nanoparticles of a more uniform size, and increases the likelihood of the nanoparticles 









4.4.2 Test that the Nanoparticle can Attach to Streptavidin 
When nanoparticles and nanoparticle conjugates are placed on slides and 
subsequently washed off, the particles that remain are those that successfully bound to the 
surface of the slides.  A larger number of particles adhering to the microscope slides 
indicates stronger intermolecular interactions between the particles and the surface of the 
slides.  This is because stronger interactions cause more particles to adhere to the slide 
despite the slide being washed.   
According to Table 7, in both trials, nanoparticle-streptavidin conjugates on 
biotin-coated slides yielded by far the largest result of the four conditions tested.   This 
suggests that the CSLN successfully attached to streptavidin, as the strong streptavidin-
biotin interaction allowed more nanoparticle-streptavidin conjugates to attach to the 
biotin-coated slides.  The control conditions in which nanoparticles were tested on biotin-
coated and normal slides yielded close to 0 particles.  This further confirms that the 
CSLN successfully attached to streptavidin.  This is because these results demonstrate 
that the nanoparticles themselves are incapable of attaching to the slides.  Thus, the vast 
majority of the fluorescent particles visible in the pictures of nanoparticle-streptavidin 
complex on biotin-coated slides are the result of the CSLNs successfully attaching to 
streptavidin, allowing the fluorescent nanoparticles to adhere to the biotin-coated slides 
through streptavidin-biotin interactions.   
            However, in Trial 1, nanoparticles-streptavidin on normal slides yielded a larger 
average number of particles per frame than expected.  This condition resulted in 4.3 
particles per frame, while the other two control conditions resulted in 1.1 and 0.1 
particles per frame.  This is not the case in Trial 2 though, as the nanoparticles-
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streptavidin on normal slides yielded 0.2 particles per slide, which is close to 0 as 
expected.  A possible explanation for this is that the glass slide used in Trial 1 was 
accidentally rubbed at some point, giving the slide a net charge.  Because both CSLNs 
and streptavidin are charged, the charge on the glass slide may have caused the 
nanoparticles-streptavidin conjugates to attach via electrostatic interactions.  
 
4.4.3 Test that Streptavidin can Attach to Biotin 
The purpose of this experiment was to validate and confirm that the streptavidin 
could indeed attach to biotin. Even though it is known throughout scientific literature that 
streptavidin and biotin have the strongest non-covalent attractive force that exists in 
nature, we wanted to make sure that was true in our experimental settings. In this 
experiment, we incubated the nanoparticle-streptavidin complex with excessive free 
biotin, added it to biotin-coated microscope slides, and observed the amount of 
nanoparticle-streptavidin complex that bound to the biotin-coated slides under fluorescent 
microscopy at two, four, and eight hour time points. The thought behind our experiment 
was that since streptavidin has four biotin-binding sites, the more we incubate the 
streptavidin with excess biotin, the more biotin-binding sites on streptavidin will be 
occupied, so the less chance that streptavidin can adhere to the biotin-coated slides 
(because all the biotin-binding sites on streptavidin would have been occupied by the free 
biotin). Essentially, our experiment is based on the principles of saturation. We predicted 
that the longer we saturate the nanoparticle-streptavidin complex, the less fluorescence 
will be observed on the biotin-coated slides, due to the decreased adherence of the 
nanoparticle-streptavidin complex on the biotin-coated slides.  
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Images under fluorescent microscopy at hour two after initial incubation yielded 
an average of 5 fluorescent complexes per image. In contrast, images under fluorescent 
microscopy at hour four after initial incubation yielded on average 2.8 fluorescent 
complexes per image, while images at hour 8 had on average 1.8 fluorescent complexes 
per image. 
The number of fluorescent complexes per image observed at hour four compared 
to hour two decreased by nearly 50%, and the number of fluorescent complexes per 
images observed at hour eight compared to hour two decreased by about 64%. We 
consider these to be significant results because we understand that within two hours, 
much of the biotin-binding sites on streptavidin would already have been occupied by the 
free biotin. There is still a significant difference in fluorescence observed among the two, 
four, and eight hour time points and that is a significant result. With these results, we 
confirm that the streptavidin and biotin we purchased do bind to each other in an 
attractive manner. Thus, these results indicate that the streptavidin/biotin portion of our 
ultimate nanoparticle complex will adhere and connect as expected. 
 
4.4.4 Determining the Concentration of Nanoparticles in Solution 
            The purpose of determining the concentration of nanoparticles in our nanoparticle 
solution was so that we could determine the appropriate ratios of streptavidin and biotin 
to add to make the complex in order to maximize the number of nanoparticle complexes 
we would create. To determine the concentration of the nanoparticles in solution, we 
began by taking images of the nanoparticles under fluorescent microscopy. We took 
images in random locations on the microscope slides, so that we would receive an even 
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representation of the total slide. After taking into account the size of the microscope 
coverslip, the real size of each image, and how many nanoparticles we originally plated 
onto the microscope slide, we determined through several mathematical calculation that 
we have 3915.9 nanoparticles/µL, or roughly 4000 nanoparticles/µL.  
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5. Nanoparticle Complex with BBB Model 
5.1 Nanoparticle Complex with BBB Model Methodology 
In this stage of the experiment, both the BBB model and nanoparticle complex 
were completed and ready to be tested together to see the level of nanoparticle complex 
permeation through the BBB model. The non-complexed nanoparticle and the full-
complexed nanoparticle were each tested against the HUVEC monolayers with varying 
TNF-α, and the aggregation of nanoparticles after 1 hour and 5 hour incubation was 
imaged using phase and fluorescent microscopy.  
HUVEC cells were cultured until the fourth passage, after which they were plated 
onto fibronectin-coated, glass coverslips to produce 6 fully confluent HUVEC 
monolayers. To simulate varying degrees of inflammation in the brain, different levels of 
TNF-α were added to individual coverslips, specifically 0µg/mL, 2µg/mL, 20µg/mL of 
TNF-α. TNF-α was added to the fully confluent HUVEC coverslips 18 hours prior to the 
addition of non-complexed nanoparticle control. Two coverslips had 0µg/mL TNF-α 
(non-diseased state), two coverslips had 2µg/mL TNF-α, and another two coverslips 
20µg/mL TNF-α. After 18 hours, the cells were washed with 2 mL of HUVEC media. 2 
mL of fresh media was added to each coverslips, followed by 25µL of non-complexed 
nanoparticle solution (4000 nanoparticles/µL). The coverslips were placed in a 5% CO2 
incubator at 37°C. Three coverslips (0µg/mL, 2µg/mL, and  20µg/mL of TNF-α) were 
examined after a one hour nanoparticle incubation at 37°C in a 5% CO2 environment. 
The coverslips were imaged underneath phase and fluorescent microscopy to observe the 
aggregation of nanoparticles around the HUVEC cell monolayer. For each individual 
well, multiple images were taken of randomly chosen locations on the monolayer, using 
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both phase and fluorescent microscopy under 10x magnification. Phase images were 
captured at 250 ms exposure, and fluorescent images were captured at 100 ms exposure. 
Three additional wells (0µg/mL, 2µg/mL, 20µg/mL of TNF-α) were examined after a 5 
hour nanoparticle incubation at 37°C in a 5% CO2 environment.  
The same protocol was performed using the full nanoparticle complex, which 
included the streptavidin and biotinylated antibody attached to the nanoparticle. Images 
taken from both the control and experimental trials were observed and compared at their 
respective time points. 
 
5.2 Nanoparticle Complex with BBB Model Data and Results 
5.2.1 Nanoparticle Control Results 
 
Figure 49. Composite images of bare nanoparticle absorption by HUVECS when 
incubated with no TNF-α at 1 hour (left) and 5 hours (right). Absorption greatly increases 
with time, with many more fluorescent points. Red fluorescence indicated the bare 
nanoparticle, as seen with the arrows.  
Images were analyzed using a combination of ImageJ and MATLAB in order to 
characterize fluorescence emitted by the nanoparticle. Fluorescence resulting from the 
nanoparticles is combined with the phase images to observe localization of nanoparticle 
absorption. These results are used to compare nanoparticle absorption with the non-
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specific bead absorption kinetics as a way to differentiate kinetics and mechanisms. Also, 
the results are useful in determining the efficacy of targeting VCAM-1 using CSLNs. 
 
Figure 50. Composite images of bare nanoparticle absorption by HUVECS when 
incubated with 2 µg/mL TNF-α at 1 hour (left) and 5 hours (right). The 5 hour case seems 
anomalous with a visual decrease in fluorescence, as seen by less dense fluorescence at 
points like the one denoted by the arrow. 
 
           The first set of experiments is the control: the nanoparticle without anti-VCAM 
incubated with HUVECs. The two time points match the bead experiments. On initial 
visual inspection, the one hour time point for each level of TNF-α shows low levels of 
nanoparticle absorption, less so than non-specific bead absorption. Fluorescence is clearly 
visible, indicating that the fluorescent signal is distinguishable from the background. 
Among the three samples taken at each level of TNF-α, each has a clear drop in 
fluorescence once the MFIs are taken into account. With no TNF-α present, the MFI is 
3.3 averaged across 4 groups, as seen in Figure 49. However, there is a single point that 
was an outlier, with the MFI of 1 instead of 3 or 4. Removing the outlier, the MFI 
average for the three samples becomes 4. The trend in fluorescence in the presence of 
TNF-α is more or less the same as previous experiments. When observing HUVECs 
incubated in 2 µg/mL TNF-α, the MFI is 3.8 for 3 groups (Figure 50), but at 20 µg/mL 
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the MFI drops back to 3.3 (Figure 51). This result is not unsurprising given the results 
from the bead experiments, where the MFI for the 20 µg/mL is lower than the 2 µg/mL 
sample. The MFIs correspond to a decrease of approximately 7.2x and 6.6x in 
fluorescence as compared to the bead experiments. Since the nanoparticles and beads are 
not directly comparable, the difference in magnitude is less important than the trends in 
absorption. 
           Some of the same trends from the bead experiments carry over besides the 
fluorescence intensity trends. The increasing levels of TNF-α yields similar effects on the 
cell layer when inspecting the phase images. Disruption is evident especially in the 2 
µg/mL sample where there are many gaps in the cell layer not present in the 0 µg/mL 
sample. The same can be said for the 20 µg/mL sample, although the relative size of the 
gaps is hard to determine from the phase images. Arguably, the 20 µg/mL sample 
actually shows slightly less disruption in the cell layer. Some of the cell morphology is 
changing under the combined conditions of the TNF-α and nanoparticle.  
 
Figure 51. Composite images of bare nanoparticle absorption by HUVECS when 
incubated with 20 µg/mL TNF-α at 1 hour (left) and 5 hours (right). The 5 hour case 
shows denser fluorescence in certain areas but not necessarily more throughout as 
compared to the control case, such as the area denoted by the arrow.   
 
 117 
The five hour time point shows more fluorescence, as expected, but once again 
not to the degree of non-specific absorption. Visually, there is an increased number of 
nanoparticle clusters in the 0 µg/mL sample. This indicates that during the initial 
incubation period, not many cells absorb the nanoparticles. Also, the fluorescence at 
these clusters is increasingly bright. Over time not only do cells absorb more, as 
expected, but also more cells absorb the nanoparticle based on these images.  
When the cells are not incubated with TNF-α, the resulting MFI is 7.6, an increase 
of 2.3x over the four hours. Each sample has 3 trials. The increase is in line with the non-
specific bead absorption kinetics, implying that absorption kinetics are similar but differ 
by a constant. In other words, the magnitude of absorption is lower with the bare 
nanoparticles, but the rate of change of absorption is similar to the beads. 
There is a degree of uncertainty in the results once TNF-α is added. Visually, the 
fluorescence at 2 µg/mL is much lower than the other two levels, and even on par with 
the one hour time point. The drop is seen across all three samples taken at 2 µg/mL. As 
all three samples are taken from the same set of cells, it is likely that the cells were sub-
optimal in some way, causing all results taken from the well to be distorted.  
           The MFI of the 2 µg/mL sample is only 4.1, showing that the drop in visual 
fluorescence is substantiated by the overall mean of the pixel intensities. The MFI is 5.9 
for the 20 µg/mL sample, a slightly better result but still not matching the sample without 
any TNF-α. The increase between time points is only 1.8x in this case, a drop from the 





Figure 52. Bare nanoparticle absorption trend in relation to TNF-α. There is a general 
decrease in fluorescence compared to TNF-α, although not as noticeably logarithmic as in 
the bead absorption. 
Some of the trends are still in play. Overall there was a decrease in nanoparticle 
absorption in relation to TNF-α, as seen in Figure 52. This is similar to the bead 
absorption. For the data without the outlier, there is a clear decrease at the 1 hour time 
point between the 2 and 20 µg/mL samples, with only a small difference between the 0 
and 2 µg/mL samples. For the 5 hour, the differences are thrown off slightly by the 
anomalous data points for the 2 µg/mL sample. Regardless, we are not necessarily seeing 
a logarithmic decrease in absorption this time, but this could potentially be due to small 
sample sizes used. There is the possibility that these results reflect a similarity of the 
































5.2.2 Nanoparticle Complex Results  
 
Figure 53. Composite images of nanoparticle complex absorption by HUVECS when 
incubated with no TNF-α at 1 hour (left) and 5 hours (right). Fluorescence shows dense 
absorption within several cells rather than across most cells, as seen by the density in the 
cell with the arrow.  
 
           With the baseline non-specific and baseline nanoparticle absorption kinetic 
behaviors, it is possible to compare the control kinetics with the kinetics of the full 
nanoparticle complex. Also, it is possible to infer the specificity of the targeting 
mechanism by observing the fluorescence intensity distributions as compared to the 
previous control experiments. Images were once again analyzed with a combination of 
MATLAB and ImageJ.  
            The pattern for the full nanoparticle complex is similar to the bead experiments. 
Upon visual inspection, there does not seem to be much different between the bare 
nanoparticles and the nanoparticle complex. Cells at the one hour time point show a level 
of cell layer degradation typically seen in the presence of TNF-α. This is particularly odd 
as even in the sample incubated without TNF-α there is noticeable morphology changes. 
The trend extends to the other samples, although the disruption is more in the monolayer 
and less in the morphology.  
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Figure 54. Composite images of nanoparticle complex absorption by HUVECS when 
incubated with 2 µg/mL TNF-α at 1 hour (left) and 5 hours (right). Once again, maximal 
fluorescence occurs in this sample.   
 
At the one hour time point, the MFIs at the three levels of TNF-α are 13.3, 14.2, 
and 12.4 in increasing order. These correspond to Figures 53, 54 and 55 respectively. 
Seeing a decrease in mean fluorescence for the 20 µg/mL sample is no surprise now and 
at this point can be attributed to the degradation of the monolayer. The important note is 
that the MFIs are much higher than the nanoparticle control; the ratio of MFIs between 
the experimental and control group comes out to be 4.1, 3.7, and 3.8, with 3 trials for 
each sample.  This is a relatively large difference when compared to the increase over 
time for the bare nanoparticles.  
A result of note is that absorption at one hour is moderately higher than with the 
bare nanoparticle. This result indicates that the nanoparticle complex absorption kinetics 
begins at a higher rate than in non-specific absorption. However, the result for the 0 
µg/mL sample is strange. There is little VCAM-1 expression in the staining as seen in the 
previous section, and yet the absorption of the nanoparticles with anti-VCAM-1 attached 
is very similar to the other levels of TNF-α. It is possible that even baseline VCAM-1 
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expression is enough to cause absorption of the nanoparticle complex or the absorption 
mechanism is not as expected.  
 
Figure 55. Composite images of nanoparticle complex absorption by HUVECS when 
incubated with 20 µg/mL TNF-α at 1 hour (left) and 5 hours (right). The 5 hour shows a 
large increase in fluorescence, but once again it is not evenly distributed through the 
cells. A dead patch is shown with the arrow.  
At the five hour time point, results show the typical increase in fluorescence, 
although not to the same degree as with the beads. Once again, more fluorescence is seen 
throughout the cell layer; the clusters of fluorescence are typically denser, resulting in the 
increase of overall fluorescence seen in the image. However, only in the sample 
incubated in 20 µg/mL TNF-α is there a marked increase in the number of clusters. The 
MFIs match the observation; for the three levels, the MFIs are 18.4, 18.5, and 18.5. This 
is the first time that the spread has been so small, although this could be a result of the 
wildly varying results seen at the one hour time point as well.  
When comparing the effects of TNF-α on the cell layer to other experiments, it 
seems that the five hour time point shows far less change than in the one hour time point, 
and even possibly in other experiments. There is a slight morphological change as the 
level of TNF-α increases, but the amount of disruption is fairly constant throughout the 
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increase in TNF-α. This could possibly be an explanation for the relatively small 
difference seen in the MFIs at the five hour time point. 
The ratio between the five hour time point MFIs of the complex and control 
samples is smaller than at the one hour time point. It is only approximately 2 or 3 this 
time; 2.4 for the 0 µg/mL sample and 3.1 for the 20 µg/mL sample. It is hard to 
determine exactly what the ratio is for the 2 µg/mL sample given that the control had an 
anomalous data point. However, it is safe to say that the ratio decreases from the one hour 
to the five hour time point when compared to the control experiments. Thus the 
nanoparticle complex has slightly different absorption kinetics than both the non-specific 
case and the bare nanoparticle case. Based on the two time points, the complex has more 
rapid initial absorption but slows down. The complex would then most likely reach 
critical concentrations in the specimen sooner than a bare nanoparticle.  
Once again the MFI of the 0 µg/mL sample is disturbing. Despite the lack of 
VCAM-1 expression, the absorption is undisturbed. Should the MFI have remained at the 
previous level, the results would be more reasonable. However, now the question arises: 
by what mechanism is the absorption achieved? Clearly the level of VCAM-1 expression 




Figure 56. Nanoparticle complex absorption trend in relation to TNF-α. The trend is no 
longer a general decrease. Instead we see a biphasic trend at the 1 hour time point, and a 
flat amount of fluorescence for the 5 hour time point. 
An interesting note to make for the nanoparticle complex is the different 
absorption trend in relation to TNF-α. In the beads as well as the bare nanoparticle results 
(with the outlier removed), we saw a general decrease in absorption in relation to TNF-α. 
Despite the anomalous data point for the control at the 5 hour time point, the trend is still 
very similar. This is in contrast with what we see in the nanoparticle complex absorption, 
as seen in Figure 56. What we actually see instead is a biphasic trend, with the maximal 
amount of fluorescence occurring in the 2 µg/mL group instead of the 0 µg/mL group. 
This is not necessarily evident at the 5 hour time point though, as all the groups show 
very similar fluorescence. However, it is clear at the 1 hour time point that the absorption 
trend is different than the bare nanoparticle absorption. The results show that the 
mechanism is most likely different from non-specific absorption seen in both the beads 




























5.3 Nanoparticle Complex with BBB Model Discussion 
5.3.1 Discussion of Image Trends 
Many of the same trends seen in the VCAM-1 staining and bead absorption 
experiments are once again seen in the nanoparticle absorption experiments. TNF-α has 
expected effects on the cell layer, although these results did not necessarily translate to 
increased fluorescence. In both sets of experiments, gaps between cells increased as TNF-
α also increased. With cells covering a smaller area, there should be less fluorescence, 
which is seen for the 20µg/mL samples in both the control and the experimental groups.  
The reduced cellular area is in competition with the effects of TNF-α though. At 2 
µg/mL, the fluorescence increases across almost all samples, from the HBMECs through 
the complex. The only exception is the one hour time point for the nanoparticle 
absorption experiments where the mean fluorescence drops. It is somewhat strange that 
we would see a sudden drop in only that particular sample. The possibility arises that the 
sample was affected in some way before the experiment that caused variations we did not 
expect to see. It makes it hard to compare the fluorescence values with the five hour time 
points and other data sets. 
Aside from that sample, we can expect that these results are reasonable. Then, as 
previously mentioned, at 20 µg/mL the fluorescence goes back down compared to the 
2µg/mL samples. TNF-α acts both to disrupt the monolayer and signal cells to increase 
absorption. As we can see, one effect is more dominant at certain levels.  At higher 
concentrations, there is less cellular area and thus less area for fluorescence to appear, 
reducing the mean fluorescence. At lower concentrations, the cell signaling is the 
predominant effect. 
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One of the difficulties in comparing the nanoparticle images is the lack of a 
background stain to compare the fluorescence with. In the VCAM-1 staining 
experiments, the resulting VCAM-1 fluorescence can be compared to other images by 
normalization based on the number of cells seen in nucleus stains. While in that case, the 
normalization was not necessary given the coverage of VCAM-1 in the samples, it is 
more important in the absorption experiments. Without a full monolayer present, the total 
cellular area is not approximated by the total area of the image. Normalization would 
then make sense to compare fluorescence per cell as opposed to overall fluorescence. 
Without a way to accurately quantify either the number of cells aside from counting them 
in the phase image, normalization would not represent the fluorescence well. Even 
counting cells in the phase image is difficult as cell morphology changes make cells hard 
to differentiate at points. Normalization may bring the MFIs for the 20 µg/mL samples 
back in line with the trends seen in the VCAM-1 experiments, although that is not a 
guarantee.  
 
5.3.2 Ranging Effects of TNF-α on Endothelial Cells 
TNF-α is a cytokine present during the inflammatory response, but its actions are 
not limited to just the regulation of cell adhesion molecules. TNF-α can additional cause 
the release of other cytokines and other chemotactic factors.98 The cellular cascades that 
these other cytokines may be similar to the actions of TNF-α or entirely different, 
therefore we are unable to take into account the inevitable physiological changes not 
resulting directly from TNF-α. TNF-α inhibits cell growth, causes cytocidal activity, 
modulation of gene expression, activation of g proteins, modulation of protein 
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phosphorylation.99 Overall, TNF-α can cause endothelial damage and increased 
perfusion.100 These physiological and architectural effects are illustrated with the addition 
of 2µg/mL and 20µg/mL of TNF-α, with significant gaps apparent in the monolayer of 
HUVEC cells in both the control and full complex tests.  
The lack of a monolayer in portions of the coverslips may have contributed to the 
inconsistent findings within the control and full complex results at 20µg/mL, because 
both types of nanoparticles could have aggregated in those open areas instead of binding 
primarily to the HUVECs. The aggregation of particles due to the changes in morphology 
also could have either prevented the removal of unbound particles during washing due to 
interactions with the cytoskeleton or exasperated the removal of unbound nanoparticles in 
gaps in the monolayer. These two factors could have played a factor in the unexpected 
fluorescent patterns going from 2µg/mL and 20µg/mL of TNF-α. Overall, the 
physiological and architectural changes to our HUVEC monolayer after the addition of 
TNF-α could have contributed to the inconsistency in fluorescence and apparent 
nanoparticle binding.  
 
5.3.3 Cell-Adhesion Molecule Targeting Capabilities 
As stated in the background section about the blood-brain barrier, during diseased 
states, infected cells secrete TNF-α to produce the inflammatory response. VCAM-1 is a 
cellular adhesion molecule that is up-regulated during these states as a result of cellular 
cascades. VCAM-1, however, is not immune to other physiological changes and also 
requires the use of other receptors. VCAM-1 expression is also coupled with oxidative 
stress caused through oxidation-reduction reactions, which can additionally affect 
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transcriptional and translational pathways within the HUVEC cells.101 This additional 
molecular consequence could have altered expected levels of cell adhesion molecule 
expression in a way that we are unable to account for. The activation of nuclear factor 
NF-κB seems to involved in these redox reactions with VCAM-1, and is involved in the 
cellular cascades that help create the inflammatory conditions, relating back to the 
changes in morphology in our HUVEC monolayers.98 VCAM-1 appears to be dependent 
on NF-κB to mediate leukocyte binding to ECs.101 
VCAM-1 is also dependent on a counter receptor, VLA-1 that is present on 
monocytes and lymphocytes.101,102 The interaction of these two molecules facilitates the 
binding of leukocytes to the ECs in general, and the lack of this additional receptor on 
our nanoparticle complex may contribute to the lack of efficient binding to our HUVEC 
monolayer. In relation to the binding of nanoparticle complex to cells bathed in no TNF-
α, there could be some underlying expression of VCAM-1 in the HUVECs. Such weak 
expression was found in other types of ECs, but this should not impede our nanoparticle 
binding.103 This reasoning could explain why there is baseline aggregation/attachment of 
our nanoparticle complex to our HUVEC monolayers at 0µg/mL of TNF-α. However, we 
are unable to assess the degree of this binding in comparison to aggregation of clusters 
around the monolayer itself.  
Other cellular adhesion molecules, such as ICAM-1 and E-selectin receptors are 
additionally present on the surface of the HUVEC ECs.101,102 TNF-α greatly increases the 
mRNA expression of these cellular adhesion proteins.98 The two other receptors also help 
bind leukocytes to the ECs through specific ligand interactions. The expression of these 
molecules on ECs occurs at similar time periods: E-selectin has a maximum expression at 
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4 hours, and then decreases after 24 hours, ICAM-1 has a maximum expression at 12-14 
hours and stays elevated for several days, and VCAM-1 has a maximum expression at 12 
hours, and then slowly declines over several days.102  
The TNF-α incubation period for all of the nanoparticle tests were roughly 18 
hours, therefore numerous cell adhesion molecules were present at close to maximum 
level during our VCAM-1 nanoparticle-complex test. The overall time-dependent 
increase in several important cell adhesion molecules on the HUVECs could be one 
reason why the there was some inconsistencies in fluorescence at differing TNF-α levels 
and time points. The nanoparticle complex theoretically should have primarily interacted 
with elevated VCAM-1 levels, and fluorescence should have been greater compared to 
the nanoparticle control. This may have been present initially after the additions of the 
nanoparticle complex, as absorption kinetics begin at a higher rate compared to non-
specific interaction after 1 hour incubation. However, the increase from 0µg/mL to 
2µg/mL and then finally to 20µg/mL of TNF-α did not show a substantive trend between 
the control and full complex. Additionally, the VCAM-1 expression may have decreased 
over time between the one and five hour time points, since this was past the maximal 
expression time point (testing was performed at 18 hours), thus causing additional 
discrepancies in fluorescence between the one and five hour time points. The additional 
interaction of the nanoparticles with the additional up-regulated cell adhesion molecules 
may somehow disrupt or inhibit binding to VCAM-1 receptors, thus reducing the 
apparent fluorescence upon observation. However, this is theoretical speculation, and we 
are unable to prove that this is a hindering consequence of TNF-α addition.  
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While the research on VCAM-1 as a targeting prospect is still in development, 
much research exists on the efficacy of ICAM-1 as a possible means for drug-delivery. 
ICAM-1 is also upregulated during inflammatory conditions, and mediates attachment of 
all classes of leukocytes to the EC.102,104 Additionally, ICAM-1 has been found to aid in 
the actual transmigration of leukocytes through the EC itself, and thus can aid in 
transmigration through the BBB.104 VCAM-1 has been found to be sensitive to 
deregulation, but ICAM-1 however, is not sensitive to this mechanism.101 The two classes 
of cell adhesion molecules may have similar expression mechanisms at the onset of 
inflammatory conditions, but the steady expression of these cell adhesion molecules is 
different.  ICAM-1 can be internalized back into the cell membrane, but then reappear on 
the surface through molecule recycling mechanisms.74 It is not known whether or not 
VCAM-1 posses this internalization capability, as there are many contradictory studies.103 
One study that used immunoliposomes targeted to VCAM-1 showed that the liposomes 
bound specifically to VCAM-1, and that some of them were taken up by clathrin coated 
vesicles, but the authors cited the need for additional experiments to confirm the 
internalization.103  
This recycling property has posed as an attractive target for drug-delivery because 
it provides a pathway for recurrent drug interaction on infected cells, thus having longer 
therapeutic effects. In one specific study, 50% of internalized ICAM-1 was recycled back 
to the plasma membrane relatively intact within one hour after initial internalization of 
the molecule.74 One ICAM-1 molecule can go through several rounds of internalization 
and reappearance, thus theoretically allowing for sustained drug-delivery targeting and 
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therapeutic effects.74,105 Experiments with binding of nanocarriers to multiple copies of 
anti-ICAM-1 showed endocytic uptake and intracellular delivery of internal cargo.105  
           Our novel drug-delivery carrier focuses on VCAM-1 adhesion, and while VCAM-
1 is found to work in tandem with ICAM-1 to traffic leukocytes to inflamed states in the 
brain (black), the overall efficacy of choosing VCAM-1 as a particular drug delivery 
tactic may be less significant compared to ICAM-1 research. Our experiment is purely in 
its primary trial phase, as data was only collected once for each experiment due to time 
and budgetary issues, so this conclusion can only be speculated at this time. Additional 
trials, technical refinement, and potential comparisons to ICAM-1 tests are necessary 





6.1 Blood Brain Barrier Experiments 
We created an in vitro BBB model to simulate the structure of the BBB to later 
test our nanoparticle-based drug delivery mechanism. Adding varying levels of TNF-α to 
simulate inflammation in the barrier was expected to increase expression of the cell 
adhesion molecule VCAM-1. Thus, our goals in testing the BBB model were to, first, 
determine the patterns of VCAM-1 expression under varying levels of TNF-α, then 
determine the absorption characteristics of our monolayer. In the course of our 
experiments, we were forced to simplify the properties of our model (including 
eliminating Transwell inserts and a hydrogel layer then using HUVECs instead of 
HBMECs) because of exogenous constraints such as resources and inconsistent cell 
growth. However, we were still able to conduct the appropriate experiments to meet our 
testing goals. 
In the first test of VCAM-1 expression in HBMECs, we find that VCAM-1 
expression, measured by fluorescence, increases with additional TNF-α, but in a 
logarithmic fashion. In the second experiment doing the same process but using 
HUVECs, we see that VCAM-1 expression does not continuously increase with rising 
levels of TNF-α. Instead, it increases at the second level then decreases back to baseline 
at the maximum level of TNF-α. Finally, we tested non-specific absorption properties of 
the HUVEC monolayer using fluorescent beads. The results are similar to the HUVEC 
VCAM-1 staining experiment. There are higher concentrations of fluorescence at later 
time points (more at 5 hours compared to 1 hour), but the pattern of VCAM-1 expression 
at increasing levels of TNF-α actually decreases much like the second experiment.  
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Although the magnitude and pattern differ between HBMECs and HUVECs in 
VCAM-1 expression through fluorescence, there is a noted up-regulation in fluorescence 
with the addition of TNF-α. This similarity makes HUVECs an appropriate proxy for 
HBMECs in our model to test with the drug delivery mechanism. To test the absorption 
properties of the model using HUVECS, we added fluorescent beads, the uptake of which 
we hypothesized would increase over time and with more TNF-α. We found that 
absorption actually decreased at higher levels of TNF-α, but that there is increased 
absorption over time, which may be because of deterioration of the simplistic monolayer 
with the introduction of beads.  
The testing of our BBB model resulted in some inconsistencies and unexpected 
results, providing more understanding into the limitations of our simplistic model. 
However, we were able to discern in some capacity that there is up-regulation of VCAM-
1 expression with added TNF-α that increases absorption, which makes VCAM-1 an 
appropriate targeting molecule on our model for the drug delivery mechanism.  
 
6.2 Nanoparticle Complex Experiments 
After taking the necessary steps to create the nanoparticles, we had to 
quantitatively and qualitatively assess nanoparticle formation. Newly formed, unfiltered 
nanoparticles were non-uniform in size and shape. Moreover, the unfiltered nanoparticles 
displayed a wide range of sizes. Since diverse nanoparticle morphology is unsatisfactory 
for our purposes, we passed newly formed nanoparticles through a 0.200 µm filter. The 
filtered nanoparticles displayed greater size uniformity, lower average size, and smaller 
distribution of sizes than the unfiltered nanoparticles. Filtration not only produced smaller 
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nanoparticles, but also decreased variability in nanoparticle morphology. This ultimately 
increases the chance of our nanoparticles to pass the BBB. Thus, filtration allowed us to 
bypass a limiting factor in BBB permeation 
We then added streptavidin to the nanoparticles, as the nanoparticle-streptavidin 
complex constitutes half of our overall nanoparticle complex. Since the binding of 
nanoparticles to streptavidin is a limiting factor in forming the overall nanoparticle 
complex, we had to confirm that streptavidin successfully attached to nanoparticles. We 
found that nanoparticle-streptavidin complexes exposed to biotin-coated slides displayed 
the greatest number of fluorescent particles. Also, there was no particle visualization 
when nanoparticles with no streptavidin bound were placed on biotin slides. As a control, 
nanoparticles placed on a biotin free slide displayed insignificant numbers of particles. 
Due to the strong affinity of biotin and streptavidin, these findings suggest that 
nanoparticles successfully bound to streptavidin. 
We also had to determine if the nanoparticle-streptavidin complex could attach to 
biotin, since this is another checkpoint to complex formation. Though past research 
suggests streptavidin and biotin have a strong affinity for each other, we had to 
quantitatively confirm this affinity to eliminate potential sources of error. Due to limited 
binding sites on streptavidin and principle of saturation, we expected that increased 
incubation time (two, four, and eight hour incubation times) would decrease counted 
nanoparticle-streptavidin complexes. This trend was significantly produced, suggesting 
that nanoparticle-streptavidin complex did bind to biotin. 
We also found the concentration of filtered nanoparticles in our solution, which 
would allow us to later determine an appropriate ratio of streptavidin and biotin to add to 
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solution of nanoparticles. An appropriate ratio is needed to maximize the number of 
combination nanoparticle complexes. We found roughly 4000 nanoparticles/µL. 
Our quality control tests for our nanoparticles displayed that filtered nanoparticles 
would be ideal for our purposes. Moreover, the nanoparticle-streptavidin complex was 
found to be stable and able to bind to biotin. Furthermore, knowing the concentration of 
nanoparticles in our solution, we can effectively form the end-stage nanoparticle complex 
with confidence that intra-complex interactions will be strong enough to support the final 
complex as we perform combination experiments.  
 
6.3 Combination Experiments 
We performed fluorescent imaging of the combined nanoparticle complex. 
Specifically, we performed MFI on a control group, involving the nanoparticle complex 
without anti-VCAM-1 incubated with HUVECs, and an experimental group consisting of 
the nanoparticle complex with anti-VCAM-1 incubated with HUVECs. 
We found that the MFI in the experimental group was twice as great as the MFI in 
the control group. This suggests that targeting VCAM-1 successfully increases absorption 
of the nanoparticle complex into the cell layer. Moreover, this trend is seen across all 
levels of TNF-α. Generally, we found greater MFI measurements as incubation times of 
the cells were increased. MFI was also greater as the concentration of TNF-α was 
increased.  
However, the cells displayed slight morphology changes as TNF-α levels were 
increased, but the observed amount of disruption was consistent throughout all levels of 
TNF-α. In essence, we confirmed that greater amounts of TNF-α do increase space 
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between cells. Moreover, cells covering a smaller surface are expected to display less 
fluorescence. Though surface area changes are in competition with TNF-α levels, we 
found this trend to hold true with 20 µg/mL samples, but not other samples. We also 
observed an unexpected sharp decrease in MFI at the one hour mark for nanoparticle 
absorption experiments. 
In essence, we found that TNF-α significantly disrupts cell monolayers to increase 
absorption of our nanoparticle complex. Still, there is a push-pull mechanism to consider. 
At greater concentrations of TNF-α, there is less cell surface area, which in turn limits the 
amount of measured fluorescence. At lower levels of TNF-α, cell signaling to absorb the 
nanoparticle complex is predominant.  
VCAM-1 expression is also mediated by other cellular mechanisms, which we did 
not account for with our experiments. Also, VCAM-1 is not the only cellular adhesion 
molecules found in HUVECs. Since all cellular adhesion molecules are expressed more 
so in the presence of TNF-α, their presence contributes additional bias to our results. 
 
6.4 Experimental Considerations 
6.4.1 Creating a More Accurate in vitro BBB Model 
First, our in vitro BBB model was a simplistic design that did not incorporate 
many other aspects of the in vivo BBB such as pericytes and astrocytes.58 Because of 
resource and time constraints, we decided to create a simple monolayer of ECs. We had 
originally planned to use Transwell inserts and a hydrogel layer to both better simulate 
permeation and be better able to analyze volume of final nanoparticles. Unfortunately, 
forming a monolayer on the Transwell inserts using either the HBMECs or the HUVECs 
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was problematic. After multiple attempts to produce a Transwell monolayer did not work, 
we had to adapt our in vivo BBB by using endothelial cells on glass coverslips. Creating a 
more complex, realistic in vitro BBB would allow us to obtain more realistic results and 
make more relevant conclusions. Additionally, our model used HUVECs instead of 
HBMECs because we had difficulty maintaining the HBMEC lines. Although HUVECs 
have similar properties as HBMECs because they are both ECs, HBMECs are more 
useful to study transport across the BBB because they have been shown to have higher 
TEER values than HUVECs. This means that HMBECs would have provided tighter 
junctions and been more representative of an in vivo BBB.106  Again, since we were 
limited by time, we could not improve upon our HBMEC culturing methods or repeat our 
experiments using a model made of HBMECs. We were limited to plating HBMECs onto 
fibronectin, so we were unable to accurately represent the BBB as described by other 
model studies, which primarily use co-culture techniques in Transwell inserts. Co-culture 
techniques produce a more physiologically viable BBB due to the release of chemical 
mediators from accessory cells (astrocytes and pericytes). Lastly, the addition of flow 
would be highly beneficial in simulating in vivo conditions and could cause significant 
changes in our results. Creating a more complex, realistic in vitro BBB would allow us to 
obtain more realistic results and make more relevant conclusions.   
Biologically, TNF-α is expressed in much smaller quantities than those used in 
our experimental trials. We chose the levels of 0µg/mL, 2µg/mL, and 20µg/mL to 
provide a significant difference that would allow for visualization of nanoparticle 
complex transmigration. Now that we have concluded that our drug delivery complex 
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does indeed use VCAM-1 targeting, we would complement a more realistic BBB model 
with more biologically relevant TNF-α concentrations. 
 
6.4.2 Fine-Tuning Nanoparticle Creation 
Our nanoparticle complex also could have benefitted from more fine-tuning to 
create even smaller and more uniform particles.  Our ability to minimize and homogenize 
the size of our nanoparticles was limited, because our sonicator was limited to a 
frequency of only 60 Hz, while previous studies involving CSLN sonicated their 
nanoparticles at 20kHz.29 Our ability to measure the size and uniformity of our 
nanoparticles was also limited. We were able to limit the size of our nanoparticles to 
below 200 µm in diameter by filtering the nanoparticle solution through a 200 µm filter. 
The sizes of our nanoparticles were analyzed rudimentarily through ImageJ analysis, but 
more precise estimates and numbers could have been obtained using a Zetasizer 
instrument. 
 
6.4.3 Nanoparticle Complex Physiological Side Effects 
It is also important for us to understand the physiological side effects of our 
nanoparticle complex on the BBB. Possible toxicity in the nanoparticle components or 
media could have been detrimental to the cells in our BBB model.  We could have could 
have assessed the toxicity of our nanoparticles by applying them at different 
concentrations to cultures of HUVECs, and comparing our results against negative 
control groups. While we attempted to detoxify our nanoparticle solution by filtering it 
through a 200 µm filter to filter out any existing bacteria, the process could have been 
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enhanced by performing all of our experiments under sterile conditions (i.e. in a sterile 
hood). While our filtering of the nanoparticle solution significantly decreased the amount 
of contamination experienced on our BBB model, there was still a lot of debris that could 
have been minimized through sterilization techniques. 
In our experiments, we only added a fixed concentration of the nanoparticle 
complex, which may or may not have caused the individual particles to aggregate. It 
would be of interest to replicate our experiments using varying concentrations of the 
complex in order to investigate the complex’s aggregating properties, and whether this 
benefits its transmigration.  
  
6.4.4 Conducting Multiple Trials 
Lastly, time and resource restraints prevented us from conducting as many trials 
in each experiment as we had originally intended. Local fluctuations in cell fluorescence 
in our samples may have skewed our results since we had too few samples. To obtain 
more definitive results, we would want to repeat each control and experimental trial at 
least three more times. The data presented in this paper is therefore preliminary, and 
should be reconfirmed through additional experimentation using the same methodology.  
 
6.5 Future Directions 
Drug delivery through the BBB is a topic with immense potential in the medical 
field. It has important implications for neurological diseases and understanding of 
physiological functions. There is much more work that can be done to perfect these 
methods and save more lives. 
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6.5.1 In vivo BBB Model Experiments 
An important next step in BBB experiments would be to conduct experiments in 
vivo. This would allow us to test how our drug delivery mechanism would actually 
interact within the body and bring to light the many other factors to consider when in a 
complex environment. In vitro environments may attempt to capture in vivo conditions as 
much as possible, however, there are still physiological characteristics that are difficult to 
recreate in an external setting; for example, the heterogeneity of VCAM-1 up regulation 
in the brain.  Once in vitro data is confirmed with additional experiments, in vivo 
experiments should be proposed to consider our drug-delivery capabilities in an 
organism. The goal of our project was to see if our nanoparticle complex was able to 
migrate across the BBB more efficiently than current drug delivery methods. The next 
step is to determine how the drug would be released from the nanoparticle complex into a 
specific region of the brain once it passes through the BBB.  
 
6.5.2 Drugs to Replace Fluorescent Dye 
Eventually, nanoparticle carriers will need to include actual drugs to treat 
neurological diseases instead of fluorescent dye substitutes. This would allow 
investigators to both determine the interaction of drugs within the nanoparticle complex 
and better simulate actual release of drugs into the body. This is an important step 
because of the current dearth of neurological drugs whose development is hindered by the 
inability to penetrate the BBB. The amount of neurological drugs would have to increase 
by 500% to be comparable to cardiovascular drugs.107 Since only small, hydrophilic 
molecules can cross the BBB, this limits the kinds of drugs developed. Many of the most 
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prominent afflictions, such as Alzhiemer’s, brain cancer, stroke, Huntington disease, and 
amyotrophic lateral sclerosis (ALS) cannot be treated drugs of this size. Creating viable 
methods for other objects to traverse the BBB would spur more research and 
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